Department of Clinical Physiology, Nuclear Medicine & PET

Annual Report 2019

Rigshospitalet · University of Copenhagen Contents

Preface...... 2 Mission and objectives...... 4 Organisation and staff 2019...... 6 Highlights 2019...... 10 Clinical physiology and nuclear medicine...... 12 PET/CT ...... 14 Artificial intelligence...... 16 Cardiac investigations ...... 18 Imaging of angiogenesis ...... 20 Pediatric Nuclear Medicine...... 22 Rigshospitalet Children’s Hospital...... 24 King Frederik V founded Rigshospitalet in 1757. Today it has app. 1,250 beds and 12,000 Education...... 26 employees. Research at Rigshospitalet is published in more than 2,000 peer review papers Agfa RIS/PACS...... 28 per year, including >200 higher academic theses (PhD and Doctor of Medical Science). Neuro PET...... 30 Rigshospitalet is part of The Capital Region of Denmark and is a Copenhagen University MR imaging of muscle function...... 32 Hospital. PET/MR...... 34 Nuclear medicine technologists, radiographers and lab technicians...... 36 University of Copenhagen Medical secretaries...... 40 The University of Copenhagen was founded in 1479. The Faculty of Health and Medical Cyclotron Section...... 42 Sciences has 10,000 students, including medicine and bioengineering in collaboration with Radiochemistry Section...... 44 The Technical University of Denmark, DTU. The University of Copenhagen is member of Academic and other activities...... 48 IARU, the International Alliance of Research Universities and LERU, League of the European Equipment 2019...... 53 Research Universities. www.ku.dk Studies 2019...... 54 Finance...... 57 Publications...... 58 Podcasts...... 67 Cluster for Molecular Imaging...... 68 Research...... 72 Collaboration with The National Hospital of the Faroe Islands...... 78 Neurobiology Research Unit...... 80 Bioengineer in Medicine and Technology ...... 82 Preface

In 2019 we received a generous donation from the do research as an interdisciplinary effort and all 2019 was a year with many celebrations; Linda M. Thank you very much to Bettina Lundgren for 10 John and Birthe Meyer Foundation of 43,7 mio. groups are involved: Nuclear medicine physicians, Kragh, our Chief Nuclear Medicine Technologist good years as our center director. Bettina Lundgren DKK for a new PET/MRI scanner and research radiologists, physicists, bioengineers, mathema- celebrated her 40 years anniversary as nuclear got a new prestigious job and left the hospital end on artificial intelligence. It was an overwhelming ticians and IT experts, radiochemists, nuclear medicine technologist at Rigshospitalet, and she of August 2019. Vice Director Lene Ørnstrup Chris- gift, and we are honored, grateful and privileged. medicine technologists, radiographers and many was praised by all of us as a unique and wonderful tensen were then both acting director and vice We would like to express our most sincere thank others. leader. She also received the prestigious award director with two jobs for more than half a year. you. It will be implemented in 2020 in new prem- from the hospital: “Årets bioanalytiker 2019”, or Thank you for all your work and the helpful collab- ises in the Finsen building. It will be a major step In 2018 we reported problems with the newly in English: “This year’s technologist 2019”. oration. Thank you to the Department of Radiol- forward for our department and most important implemented Agfa RIS/PACS ICT system for ogy, Head of Department Ilse Vejborg and Chief for our patients and research. We got our first new picture archiving and patient reporting. Unfor- In 2019 Professor Andreas Kjær obtained the pres- Radiographer Johnny Madelung. We appreciate digital PET/CT in Summer 2019, also donated tunately, it has been an uphill struggle also in tigious Lundbeck Foundation Professorship and the positive collaboration very much. by the John and Birthe Meyer Foundation. It is 2019, as the problems continued with defect received a Knighthood for his impressive contribu- a whole new world for both patients and staff. performance, stability and speech; the essentials tions in research and innovation. The department From November 2019 Head of Department, Profes- Thank you very much to the John and Birthe of a well-functioning ICT system in a diagnostic would like to congratulate Andreas Kjær with sor Liselotte Højgaard was also acting head of Meyer Foundation for all the generosity. imaging department. Thank you to everyone for these major achievements. Department of Pathology until March 2020. It has patience and very long hours all year round due to been quite a job to try and help the Department of The department had another busy year with a the dysfunctional system. We would like to express Kate Pedersen Staff Technologist in PET cele- Pathology, who were in a crisis situation. I would higher than ever number of patient investiga- a sincere thank you to all for the stamina, securing brated her 40 years anniversary in Spring 2019, like to express a warm thank you to each and every tions, 196,889 and 176 peer review publications. patient reports in time without any waiting list. and we said thank you for her great efforts for the one at the Department of Pathology for welcoming Research is a key activity and focus area of our department throughout many years. She retired me so warmly and helping remedy the problems. department, and we have a comprehensive CAAI, Clinically Applied Artificial Intelligence, is Fall 2019 and Maria Pejtersen is the new Staff research program directed towards innovative our new research group with young people devel- Technologist in PET. A warm welcome. Maria Our aim is to deliver the best patient treatment and solutions to solve unmet clinical needs in our oping artificial intelligence for better imaging Pejtersen has initiated a close collaboration with the best research and education. Thank you to all patients. We adjust our research program to be with improved image quality and lower radiation our section in Glostrup and KF to assure the best staff members, collaborators and international clinically relevant and timely, and we have special dose – already now applied in our routine clinical use of our competences and scanners. colleagues for making this possible. focus on implementation of personalized or studies. This is very important for patients and for precision medicine in collaboration with Rigshos- staff, as it reduces the burden of radiation to all. In the Glostrup Section a new Staff Technologist pitalet’s other research groups and international Artificial intelligence is also used to shorten the Helle Møllegård Dahl took over February 2019 collaborators in Europe and the rest of the world. scan time for patients in our scanners, which is and is collaborating with Consultant Lotte Hahn You can read more about our research endeavors positive for both patients and the economy. CAAI Enevoldsen, who is head of Nuclear Medicine both in the various chapters in this little booklet. To all leader is Postdoc Claes Nøhr Ladefoged, M.Sc., at Blegdamsvej and in Glostrup. Warm welcome to Liselotte Højgaard Linda M. Kragh our research groups: a sincere thank you for the PhD together with Chief Computer Scientist Flem- Helle Møllegård Dahl and thank you to the whole Professor, Head of Chief Technologist dedicated, impressive and important work. We ming Littrup Andersen. section in Glostrup for working so diligently. Department

2 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 3 Mission and objectives

We strive to provide the best for each and every patient:

3 Clinical physiology and nuclear medicine patient investigations and treatment 3 Research at the highest international level 3 Undergraduate and postgraduate education 3 Good patient experiences through state-of-the-art quality, high patient security and focus on the wellbeing of each patient 3 The best possible everyday worklife for all staff members

department of clinical physiology, nuclear medicine & pet 5 Organisation and staff 2019 Department of Clinical Physiology, Nuclear Medicine & PET

Abrahamsen, Nynne Hejdemann, Technologist. Birch, Kirsten Junker, Technologist. Dejanovic, Danijela, MD, Consultant. LEADERSHIP Agner, Elissaveta Castella, Radiographer. Bisgaard, Line Stattau, MSc Mol.Biomed., Postdoc. Denholt, Charlotte Lund, MSc, PhD, Chemist. Al-Atabi, Susan, Technologist. Bisgaard, Sissel, MSc Med.Tech., Research Assistant. Dibenedetto, Altea Paola, MSc Pharm., Head of Department Chief Nuclear Medicine Al-Hashemi, Ibtehal, Student. Bjørling, Nina Louise, Medical Secretary. Research Assistant. Professor, MD, DMSc Technologist Alfsen, Maria Zeiler, MSc Biomed., Research Assistant. Bobruk, Daniel Abdulla, Student. Do, Manh Tan, Student. Liselotte Højgaard Linda Kragh Ahangari, Sahar, Research Fellow. Borgwardt, Lise, MD, PhD, Consultant. Dunbar, Douglas, Technologist. Ahmadi, Amir, Radiographer. Brakti, Inna, Student. Dähnhardt, Andreas, System Administrator. Albers, Mia C. Hjorth, Teaching Technologist. Brammer, Daniel, Student. Døssing, Kristina Benedikte Vangsted, MSc Biology, Albrecht-Beste, Elisabeth, MD, Consultant. Brandt, Patrick Krøll, Student. Postdoc. PHYSICIST AND Allerslev, Kathrine Bøwig, Radiographer. Brittain, Jane Maestri, MD, Senior Registrar. Einarsdóttir, Hrefna Sæunn, Registrar. RESEARCH TECHNOLOGY GROUP Alslev, Louise, MD, Consultant. Brun, Frederik Jager, Student. Elkington, Sakeena, Technologist. Amtoft, Annemarie Gjelstrup, MD, Consultant. Brus, Anja, MSc Biomedicine, PhD Student. Ellegaard, Andreas Høyby, Student. Professor, Consultant, Chief Physicist Anderberg, Lasse, Research Fellow. Calvo, Oriol Puig, MD, PhD. Engel, Trine Bjørnbo, MSc Pharm Tech, Postdoc. MD, DMSc, PhD, MBA Thomas Levin Klausen Andersen, Ditte Lindbjerg, Radiographer. Cappelen, Katrine Louise, Engineer. Enevoldsen, Lotte Hahn, MD, Consultant. Andreas Kjær Andersen, Flemming Littrup, MSc, PhD, Carlsen, Esben Andreas, MD, PhD Student. Erichsen, Laura Toft, Student. Computer Scientist. Carstensen, Laura Stentoft, Student. Esmail, Mona Jasmin Ali, Technologist. Andersen, Jane, Technologist. Choudhry, Aisha Bilal, Technologist. Federspiel, Marianne, Technologist. Andersen, Julie Bjerglund, MD, Senior Registrar. Christensen, Anders, MD, Postdoc. Fischer, Barbara Malene, MD, DMSc, PhD, Consultant. Andersen, Kim Francis, MD, Consultant. Christensen, Camilla Hell, MSc Chem., PhD Student. Fishekxhiu, Elida Sinik, Technologist. PATIENT INVESTIGATIONS WHOLE BODY COUNTER MEDICINE MANUFACTURING Andersen, Simon Surland, Student. Christensen, Camilla, Technologist. Fliedner, Frederikke Petrine, MSc Biotech., Clinical Physiology and Andersen, Ulrik Bjørn, MD, Consultant. Christensen, Esben, MSc Bio.Med., PhD student. PhD Student. PET, PET/CT, PET/MR Cyclotron Chief Chief Radiochemist Nuclear Medicine Chief Physicist Physicist, lic.scient Production manager André, Cecilie Dura, Student. Christensen, Emil Nørgaard, Student. Foldager, Annette, Teaching Technologist. Holger Jensen Asmar, Ali, MD, Staff Specialist. Christensen, Jan Damgaard, Cyclotron Technician. Folkmann, Nanna Freja, Secretary. Holger Jensen Jacob Madsen Attauabi, Mohamed, Student. Christensen, Tine Nøhr, MD, PhD Student. Fonslet, Jesper, MSc Physicist, PhD, Postdoc. Consultant, PhD Consultant, PhD Lotte Hahn Enevoldsen Annika Loft Jakobsen Awwal, Zara Amalie Krog, Radiographer. Clausen, Malene Martini, MD, PhD, Postdoc. Fosbøl, Marie Øbro, MD, Staff Specialist, PhD Student. Consultant Assisant Cyclotron Chief Radiochemist Azizi, Nadia, Radiographer. Clausen, Anne Skovsbo, DVM, PhD Student. Frederiksen, Kåre Peter, Registrar. Peter Oturai Jesper Jørgensen Nic Gillings Bashir, Asma, PhD Student. Clemmensen, Andreas Høeg, MSc Med.Tech., Frederiksen, Mette Helene Borggreen, Staff Technologist Staff Technologist Bay, Emma Therese, Student. PhD Student. Quality Coordinator. Ida Robsøe Maria Pejtersen Chief Nuclear Medicine Bendtzon, Camilla Kuhre Vildrik, Medical Secretary. Cold, Sigrid, Student. Frost, Nadia, Technologist. Staff Technologist Technologist Bentsen, Simon, MD, PhD Student. Cortsen, Annette, Technologist. Fuchs, Annette Maria, Registrar. Anne Sørensen Benzon, Eric von, MD, Consultant. Cramer, Stig Præstekjær, MD, Registrar, PhD. Gelle, Liibaan Mohamed, Technologist. Linda Kragh Staff Tehnologist Berg, Ronan Martin Griffin, MD, Staff Specialist. Daghigh, Ata, Registrar. Gillings, Nic, MSc, PhD, Chief Radiochemist. Helle Møllegaard Dahl Berthelsen, Anne Kiil, MD, Consultant. Dahan, Daniel, Cyclotron Technician. Ginsborg, Lone Agervold, Medical Secretary. Beyer, Birgit Krindel, Staff Technologist. Dahl, Helle Møllegård, Staff Technologist. Gram, Aurelie, DVM, PhD, Postdoc. Binderup, Tina, MSc Human Biology, PhD, de Nijs, Robin Vedel, Medical Physicist, MSc, Grunwald, Nicolas Konrad Voigt, Student. Senior Scientist. PDEng, PhD. Gruszow, David Jakob, Student.

6 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 7

Organisation and Staff 2019

Guldbrandsen, Kasper Foged, MD, Research Assistant. Hvass, Lars, MSc Biology, Research Assistant. Jæhger, Ditte Elisabeth, MSc Human Biology, Postdoc. Lindbjerg, Rikke Xiao, Student. Pedersen, Charlotte Hornnes, Scholarship. Slipsager, Jakob Mølkjær, PhD Student. Gæde, Mathias, Engineer. Højgaard, Liselotte, MD, DMSc, Professor, Head of Kamstrup, Danna, MSc Pharm., PhD Student. Lindberg, Ulrich, MSc Med.Tech, PhD. Pedersen, Cecilie Høeg, MSc Med.Tech., PhD Student. Sloth, Ane Beth, MSc Biomedicine, Haddock, Bryan Thomas, Chief Physicist. Department. Kastrup, Pia, Medical Secretary. Lindell, Elin, Technologist. Pedersen, Kate, Staff Technologist. Research Assistant. Hag, Anne Mette Fisker, MSc Human Biology, Iljazovska, Cejlan Zulfovska, Technologist. Keller, Sune Høgild, MSc, PhD, Computer Scientist. Linnet, Simone, Student. Pedersen, Malene Louise Thorup, Animal Technologist. Sommer, Niyan, Technologist. PhD, Postdoc, Research Coordinator. Malene Jackerott, MSc Biochemistry, PhD, Postdoc. Khare, Harshvardhan Ajay, MSc Pharm., PhD Student. Ljunggren, Anna, Technologist. Pejtersen, Maria, Staff Technologist. Stahlfest, Marianne, Medical Secretary. Halldòrsdòttir, Hòlmfridur Ròsa, MSc Biochemistry, Jakobsen, Annika Loft, MD, PhD, Consultant. Kiehn, Oliver Thistrup, Student. Loft, Mathias Dyrberg, MD, PhD Student. Petersen, Ida Nymann, MSc Chem., PhD, Postdoc. Stahr, Karin, Technologist. PhD Student. Jakobsen, Markus Hindsgaul, Student. Kjems, Ida, Service Assistant. Lykke, Eva, MD, PhD Student. Petersen, Lars Ringgaard, MSc Bio.Med., Stavnsbjerg, Camilla, MSc Mol.Bio.Med., Hanel, Birgitte, Technologist. Janowski, Patrick, Student. Kjær, Andreas, MD, DMSc, PhD, MBA, Consultant, Lykkegaard, Magnus Rønne, Student. PhD, Postdoc. PhD student. Hansen, Adam Espe, Physicist. Jayachandra, Mitta Raghava, Postdoc. Professor. Lærke, Sonja Pedersen, Lab Technician. Petersen, Lotte Pia, Service Assistant. Sunde, Christine Høj, Technologist. Hansen, Anders Elias, DVM, PhD, Postdoc. Jensen, Berit, Technologist. Kjærgaard, Karoline, Student. Löfgren, Johan, MD, Consultant. Philipsen, Frederik Ersø, Student. Svalling, Susanne, Technologist. Hansen, Camilla Josephine Teglgaard, Technologist. Jensen, Christoffer Vilstrup, Student. Klausen, Thomas Levin, MSc, Chief Physicist. Lønholm, Emmy Marie, Medical Secretary. Poulsen, Constance Eline Grandjean, MSc Pharm., Svejstrup, Waldemar, Student. Hansen, Caroline Rena Lind Hansen, Technologist. Jensen, Helle Højen, Secretary. Klavsen, Mads Fjelbro, Engineer, RIS/PACS Madsen, Jacob, MSc, PhD, Chemist, PhD Student. Svendsen, Nini Hvidtfeldt, Technologist. Hansen, Joachim Pries, Student. Jensen, Holger, MSc, PhD, Chief Cyclotron Physicist. Administrator. Chief Production Manager. Poulsen, Jákup Martin, Radiographer. Sørensen, Anne, Staff Technologist. Hansen, Mathilde Bro, Student. Jensen, Jacob Kildevang, MD, PhD Student. Knudsen, Lisbet Lomholdt, Consultant. Madsen, Jasmine Melissa, Student. Qvist, Katrine, MSc Medicinal Biology & Molecular Sørensen, Louise Sørup Lendorf, Technologist. Hansen, Naja Liv, MD, Staff Specialist. Jensen, Kim Ryder, Technologist. Knudsen, Mari Højberg, PhD Student. Madsen, Karine, MD, Staff Specialist. Biology, Technologist. Sørensen, Maja Støvring, Technologist. Hansen, Ole Michael Raun, Technologist. Jensen, Klaus Thorleif, DVM, PhD, Postdoc. Kofoed, Christian, MSc Chemistry, PhD, Postdoc. Marina, Simon Martin, MSc Mol.Bio.Med., Rasmussen,Thomas, MD, PhD, Postdoc. Saaie, Hanan Rahim, Technologist. Hansen, Sofie Lindskov, Physicist. Jensen, Mads Radmer, Staff Specialist. Korsholm, Kirsten, MD, Consultant. PhD Student. Reichkendler, Michala, MD, Staff Specialist. Tayyab, Mahvish, Technologist. Hanson, Ida Grüner, Student. Jensen, Malte Engmann Kjeldskov, Student. Kragh, Linda M., Chief Technologist. Meeske, Kirsten Langberg, Technologist. Rexhepi, Lume, Technologist. Thalund, Mathilde Ørbæk, MD, PhD Student. Hasbak, Philip, MD, DMSc, Consultant. Jensen, Martin Juul Ravn, Technologist. Krarup, Marie Manon Krebs, Student. Mollerup, Birgit Lilian, Technologist. Ripa, Rasmus Sejersten, MD, DMSc, Consultant. Toft, Cecilie Grønkær, Student. Hassan, Mariam, Technologist. Jensen, Sophie Bjørn, MSc Biochem., PhD Student. Kristensen, Anna Warncke, Student. Mortensen, Jann, MD, DMSc, Professor, Consultant. Risør, Louise Madeleine, MD, PhD Student. Tolstrup, Britt Maria Jæger, Radiographer. Haarbye, Martin Christian, Technologist. Jensen, Vibeke, Technologist. Kristensen, Kasper Birch, Registrar. Munch, Mette, Lab Technician. Rossing, Jonas Hem, Student. Tornvig, Cecilie Maja, Technologist. Haahr, Rasmus Primholdt, Scholarship. Jeppesen, Troels Elmer, MSc Chem, Postdoc. Kristensen, Lotte Kellemann, MSc Human Biology, Mouritzen, Nanna Jung, Student. Ryssel, Heidi, MD, PhD Student. Uzer, Sefika, Technologist. He, Yue, MSc Physicist, PhD Student. Jessen, Kirstine, Technologist. PhD Student. Mølvig, Bjørn Hübschmann, Student. Rønbirk, Lilian, Medical Secretary. Vandel, Julius Scheel, Student. Hecht-Hansen, Marianne, Student. Johannesen, Helle Hjorth, MD, Consultant. Kudsk, Pernille Marie, Technologist. Nielsen, Betina Sølvi, Technologist. Rønn, Vibeke, Head Medical Secretary, PA Professor Veseli, Antigona, Technologist. Henriksen, Frederikke Hurup, Medical Secretary. Johansen, Hjalte Quist, Student. Kurbegovic, Sorel, MD, PhD Student. Nielsen, Carsten Haagen, MSc Med.Tech., Liselotte Højgaard. Vestergaard, Mark Bitsch, PhD Student. Henriksen, Otto Mølby, MD, PhD, Consultant. Johnbeck, Camilla Bardram, Senior Registrar. Ladefoged, Claes Nøhr, Computer Scientist, PhD. PhD, Postdoc. Sadikovic, Edin, Student. Weihrauch, Per, Cyclotron Technician. Hercman, Alexandra Regina Nowacka, Technologist. Juhl, Karina, MSc Human Biology, PhD Student. Larsen, Bjarke Follin, MSc Ind.Med., PhD, Postdoc. Nielsen, Cora Schaumann, Technologist. Salihu, Armend, Technologist. Wessel, Mette Munk, MSc Human Biology, Hindsholm, Amalie Monberg, PhD Student. Juul, Mark Uhrskov, MSc Med.Tech., Larsen, Joachim Normann, Student. Nielsen, Jon, Registrar. Sammour, Razan Abu, Technologist. PhD, Postdoc. Holm, Stine, Technologist. Research Assistant. Larsen, Kristina, Technologist. Nielsen, Kasper With, Animal Technologist. Sandholdt, Michelle Windtberg, Technologist. Westergaard, Michelle Kaijer, Technologist, Holm, Søren, MSc, PhD, Senior Physicist. Jørgensen, Henriette Schjørring, MSc Mol.Bio.Med., Larsen, Lena Tina, Animal Technologist. Nielsen, Marcus Kristian, Student. Sass, Hjalthe Christian Reeberg, MD, PhD Student. PA Professor Andreas Kjær. Holten, Victoria, Student. Research Assistant. Larsen, Mads Rud, Student. Nielsen, Nikoline, Student. Saxtoft, Eunice, NMT, Clinical Instructor. Wieslander, Bente Krogsgaard, Consultant. Holtz, Simon Herken, MSc Molecular Biology, Jørgensen, Jennifer Solgaard, MSc Engineer BioTech., Larsen, Mette Fabiansen, Medical Secretary. Nielsen, Susanne Weile, Technologist. Schulze, Christina, Technologist. Wiinberg, Martin, Student. QA Academic. Postdoc. Larsson, Henrik Bo Wiberg, MD, DMSc, Professor, Nielsen, Tina Vikmann, Medical Secretary. Segur, Liva, Student. Wiinholt, Mette Neiegaard, Msc. Human Biology, Hougaard, Camilla Paludan, MSc Human Biology, Jørgensen, Jesper, MSc, Cyclotron Physicist. Consultant. Nørregaard, Kamilla, MSc Physicist, PhD, Postdoc. Semitoje, Gudrun, Medical Secretary. Technologist. Project manager. Jørgensen, Jesper Tranekjær MSc Human Biology, Law, Ian, MD, DMSc, PhD, Professor, Consultant. Olesen, Oline Vinter, MSc Engineer, PhD. Setterberg, Victoria, Technologist. Wikke, Tina, Technologist. Hovind, Peter, MD, DMSc, Consultant. PhD, Assistant Professor. Lehel, Szabolcs, MSc Chemistry, PhD. Olin, Anders. PhD Student. Simonsen, Helle Juhl, Technologist. Wittekind, Anne-Mette Nielsen, QA Pharmacist. Hübbe, Mie Linder, MSc Human Biology, Jørgensen, Mette Møller, Technologist. Lejre, Daniel, Student. Olsen, Naja Enevold, Registrar. Sinik, Edita, Technologist. Wittrup, Charlotte, Student. PhD Student. Jørgensen, Philip, Technologist. Lind, Camilla Louise Nordvig, Technologist. Olsen, Paw Winther, Engineer. Skougaard, Kristin, PhD, Staff Specialist. Zare, Soheil Naser, Radiographer. Hunter, Ingrid, DVM, PhD, Postdoc. Jørgensen, Rasmus, Student. Linde, Elisabeth Specht, Student. Oturai, Peter, MD, Consultant. Skovgaard, Dorthe Charlotte, MD, PhD, Postdoc. Aagaard, Christina Byrne Faurholt, MD, PhD, Postdoc.

8 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 9 Highlights 2019 Professor Andreas Kjær received Professor Andreas the 2019 Niels Kjær was received in A. Lassen prize Linda M. Kragh, our audience to thank for his research Chief Nuclear Medicine Her Majesty Queen within molecular Technologist received the Margrethe II for imaging and targeted prestigious annual award the Royal Order of radionuclide therapy. as Technologist of the Year Dannebrog (Ridder af A most generous donation 2019. The department Dannebrogsordenen). from The John and Birthe Meyer is very proud of this fine Foundation to a new PET/MRI achievement. scanner and research on AI, artificial intelligence. We are truly grateful.

In 2019 Professor Andreas Kjær continued his work in the Science and Engineering Linda M. Kragh had Committee of the 40 years Anniversary Danish Academy of as Nuclear Medicine Technical Sciences Our Head of Dept. Professor Technologist, and the department (ATV). The committee, Liselotte Højgaard had a busy celebrated with a reception with very together with a delegation winter, as she was also Acting many guests from Rigshospitalet and the of leaders from academia Professor Liselotte Højgaard Head of Dept. of Pathology, rest of Denmark. and industry, visited Delhi and ist Mitglied ins Kuratorium die from November 2019 to Bangalore, some of the leading Science and Robert Bosch Stiftung & Member of the March 2020. Engineering regions in India. The work is described in the ATV Board of Directors of the Novo Nordisk report “India land of opportunity”. Foundation”.

10 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 11 Clinical physiology and nuclear medicine

Section Head, Consultant Lotte Hahn Enevoldsen

Our department offers a variety of nuclear medi- We participate in various weekly and monthly cine and clinical physiological examinations of multidisciplinary team conferences discussing both routine patients and also for many research neuroendocrine tumors, thyroid diseases, adrenal investigations in a broad spectrum of disciplines. diseases, cardiac diseases, lung diseases, and pediatric oncology with our clinical colleagues. In addition to nuclear medicine diagnostics our section also comprises radionuclide therapy of patients with neuroendocrine tumors (177Lu-DOTATATE), patients with castration resistant prostate cancer and symptomatic bone metastases (223Ra), and patients with benign thyroid diseases (131I-Iodine).

12 department of clinical physiology, nuclear medicine & pet PET/CT

Section Head, Consultant Annika Loft Jakobsen

In diagnosis and treatment monitoring of daily work which improves our knowledge of the working part time in PET and part time in Radio- patients suffering from oncological or inflam- behavior of tumors. New indications and scanning therapy. By participating in research protocols matory diseases, personalized medicine plays procedures have been implemented as a result of in the use of FDG and other tracers for PET/CT an increasing role. PET/CT takes a natural part this work. radiotherapy planning we keep increasing our is this new paradigm in helping to depict the knowledge and expertise also in this field. right patients for the right treatment. As part 18F-FDG PET/CT is the work horse investigation in of our clinical every day work interpreting more our daily clinical life, but the use of 68Ga-Dotatoc FDG PET/CT also plays an increasing role in in the than 15,000 PET/CT scans every year, we attend and 64Cu-Dotatate for patients with neuroendo- clinical set-up for infectious diseases in depicting numerous multidisciplinary team conferences crine tumors and 68Ga-PSMA for prostate cancer involvement of organs as well as for treatment and tumor boards. This collaboration with our patients is increasing tremendously due to the monitoring due to the unique possibility to clinical colleagues is inspiring and definitely important information of disease behavior and detect even small active foci – a great help for the increases the quality of our interpretation of scan extent necessary for the choice of treatment possi- clinicians. results and understanding of the importance of bilities for these patients. good communication as well as being updated Incorporation of artificial intelligence in our clin- and well trained. Radiotherapy planning with FDG PET/CT has ical work is an ongoing and exciting new aspect been a clinical routine in our department for we have great expectations for, when focusing on The continuous involvement in research protocols almost two decades now due to a fruitful collab- the improvement of image quality, radiation dose and clinical trials testing new treatments as well oration with the Department of Radiotherapy reduction and shorter scan time. as new PET tracers is an important part of the and a unique set-up with specialists in radiology

14 department of clinical physiology, nuclear medicine & pet Artificial intelligence

Computer Scientists Flemming Littrup Andersen and Claes Nøhr Ladefoged

Since the installation of the first PET/CT in 2001, CAAI currently runs a number of projects generation can be generated using deep learning the department has grown rapidly, and is today spanning from bachelor to PhD level with a networks, and these methods have recently been performing more than 12,000 scans yearly. The strong focus on pre-graduate supervision of moved into clinical routine. Studies are ongoing to vast majority of the data is only used to diagnose computer scientist and engineer students. The show feasibility for using synthetic-CT-derived dose the single patient, and do not benefit the patients primary research areas, defined in close dialogue plans for radiotherapy in head and neck cancer and of tomorrow. With artificial intelligence (AI) this is with the clinicians, have been directed towards cervical cancer with application to the PET/MR. about to change. AI will exploit the Big Data infor- data domain translation i.e. converting MRI to mation to develop models that can aid the clinical synthetic CT images, lesion segmentation and Noise reduction, which in medical imaging decision-making and relieve the workload of some noise reduction of image data. translates to lower radioactivity dose or shorter of the more tedious and time-consuming tasks. AI scanning time both to great benefit for the has recently shown great promise in analysis of Medical image segmentation is driven by the patients, received a 2.5 million grant from Danske medical imaging especially starting with the devel- clinical needs; we have currently implemented Regioner, and several projects have been started opment of deep learning in general computer vision automatic segmentation of PE2I brain images that within this area. A reduction of the PET tracer since 2012. The techniques have been rapidly visualizes availability of the dopamine transporter dose for brain scanning is ongoing with focus adopted in medical imaging during the past few in the stratum. By deep leaning based segmenta- on dementia, where FDG PET scanning time for years with publications in the thousands and high tion in a clinical implementation, a fast analysis patient with Hodgkin’s lymphoma has already publicity at medical conferences and workshops. is provided to the physician for diagnosis of been reduced from 2 minutes to 20 sec over the Parkinson’s disease. Another project has focused lungs, and is now possible in a single breath hold At our department we have formed a program for on multiple sclerosis (MS) using MR Flair images (see figure). Clinically Applied Artificial Intelligence (CAAI) to implement white matter lesion segmentation. with the sole purpose of bringing AI into clinical Here work is ongoing for prognostic tools for MS. The programs translating AI into the clinical routine. The group is led by Computer Scientists workflow are developed on high-end computer Flemming Littrup Andersen and Claes Nøhr Correction for photon attenuation of PET images systems with Graphics Processing Units (GPU). Ladefoged, and further comprises 8 pre-graduate is critical for accurate quantitative image recon- CAAI currently operate a park of 7 servers with students, 4 PhD students, 2 postdocs and with struction and the fully integrated PET/MRI system Nvidia TITAN V or RTX graphics cards (Nvidia links to various departments at Rigshospitalet, (Siemens mMR) available at our department, but Santa Clara) instrumental for the running primarily Cluster for Molecular Imaging, Radiol- it is challenging to provide these images due to projects, a supercomputer with 8 GPUs sponsored ogy and Oncology. the lack of CT. We have shown that synthetic-CT by IBM is under installation.

16 department of clinical physiology, nuclear medicine & pet 7 Synthetic-CT with superimposed dose plans for Cardiac investigations radiotherapy in head and neck cancer patients on PET/MR. Example shows original CT (left) and synthetic-CT (right). Delineation of planning target volume and spinal cord illustrated in white

Consultant Philip Hasbak

Cardiac Rubidium PET/CT within 3 days after admission or with coronary many invasive cardiac procedures, particularly and arrhythmias. This test helps to detect areas of Rigshospitalet was the first hospital in Scandi- artery bypass graft surgery (CABG) within 5-7 complex PCI procedures including chronic total sarcoid inflammation. navia and one of the first in Europe to introduce days according to The Danish National Board of occlusions (CTOs) and bifurcation stenting. Rubidium PET/CT. A Cardiac Rubidium PET test Health. Non-invasive assessment of myocardial A MUGA (Multigated Acquisition) scan is used can provide information about blood flow to the function is an important domain of Cardiac Other cardiovascular nuclear medicine tests to study the pumping function of the heart. It heart muscle at rest and during stress, assess Rubidium PET. Traditionally, cardiac PET images Fluorodeoxyglucose (FDG) positron emission is generally used in patients with known heart damage to the heart muscle from a prior heart have been visually interpreted, using uptake as tomography (PET) cardiology viability imaging disease or in those without heart disease but attack, and provide information about the pump- a measure of function. This approach, however, is used in patients with known heart disease undergoing cancer treatment that can weaken the ing function of the heart. takes only a fraction of the full PET information or those who have had a heart attack. The test heart’s pumping function. into account. The application of tracer kinetic assesses the level of heart muscle damage by At Rigshospitalet there is a special need to modelling to dynamically measured data is able injecting glucose (sugar) and then determining Pyrophosphate imaging is used to assess the provide cardiac PET every day, since a large to extract objective measures of perfusion and/or which areas of the heart are using the glucose. presence of amyloid in the heart. This test helps to proportion of our patients with ischemic heart metabolism, depending on the tracer. While such Damaged heart muscle will not use glucose, while differentiate the different types of amyloid in the disease need an acute or sub-acute work-up that true cardiac quantification has been troublesome healthy (or recovering) heart muscle will. heart. requires quick decision making as to coronary and time-consuming in the past our new cardiac revascularisation strategy. Patients with unstable tools now makes this state-of-the-art technology Cardiac sarcoid FDG PET imaging is used in indi- Research-wise we have a close and good coopera- angina or non-STEMI should be revascularized readily available. Further, we offer CT coronary viduals with known or suspected sarcoidosis, an tion with various clinical departments. with percutaneous coronary intervention (PCI) angiography (CTCA) which is useful for planning autoimmune disease that can cause inflammation ´

18 department of clinical physiology, nuclear medicine & pet Imaging of angiogenesis

The journey towards a broadly applicable clinical PET tracer Figure 1.

Figure 3.

Professor Andreas Kjær Figure 2. Figure 4. Figure 5.

In 2012 we initiated development of a new an- (VEGF) is essential in sustained tumor growth. In cardiovascular disease, the neoangiogenesis may Figure 1. First preclinical angiogenesis PET/ be useful to select patients for anti-angiogenesis 68 68 giogenesis PET tracer and identified Ga-NOD- Accordingly, one therapeutic principle in cancer be considered highly beneficial. If a myocardial CT study using Ga-NODAGA-E[c(RGDyK)]2 therapy, e.g. VEGF antibod-ies. Following a in cancer. Arrows indicate bilateral implanted successfully completed phase I/IIa clinical trial, our AGA-E[c(RGDyK)]2 as a particularly promising is anti-antiogenesis therapy, e.g. bevacizumab infarction patient induces neoangiogenesis in the candidate. The PET tracer went through in-depth (Avastin®). This therapy is a VEGF antibody that infarcted area, this may be seen as part of a healing human glioblastoma xenograft tumors (modified angiogenesis tracer is now tested in several ongoing preclinical testing both in cancer xenograft models blocks the stimulatory effect of VEGF on angi- process and the outcome may be more beneficial from Oxboel et al. Nucl Med Biol 2014). phase II studies (images provided by Carlsen E, Clausen M, Skovgaard D et al.). (Figure 1) as well as in experimentally induced ogenesis and thereby hinders sufficient blood compared to patients where no or little neoangio- Figure 2. Preclinical demonstration of induced myocardial infarction in rats (Figure 2). In both supply for tumor growth – the tumor is “starved”. genesis is induced. The method may therefore pre- angiogenesis 7 days after experimentally Figure 4. First clinical data showing angiogenesis diseases the tracer demonstrated high uptake and a Although a compelling strategy, the response to dict final infarct size and be used for management induced myocardial infarction in a rat using PET performed on day 7 after an acute myo-cardial close correlation to degree of angiogenesis as meas- anti-angiogenesis therapy has been highly varia- strategy. In addition, the use of stem cell therapy or 68 Ga-NODAGA-E[c(RGDyK)]2. The bulls eye infarction. It is clearly seen how angiogenesis is ured in the tissue by molecular ex vivo methods. ble in many cancer types, e.g. glioblastoma and gene therapy in patients with ischemic heart disease plot to the right shows apical-antero-lateral induced in the anterior myocardial wall of the colorectal cancer. However, in responders the ef- has a major goal in inducing angiogenesis. There- neoangiogenesis corresponding to the site of heart in this patient. We hypothesize that strong Based on the encouraging preclinical data we set fect is often dramatic. One could therefore specu- fore, also within cardiovascular disease the future infarction (Bentsen S et al.). induction of angiogenesis may predict favorable forth to translate the PET tracer into human use. late whether the differences in response is caused use of angiogenesis PET may be used for practicing outcome. In contrast, if no or little neoangiogenesis As part of this process, an important question was by different levels of neoangiogenesis in the indi- precision medicine and preselect patients that are in Figure 3. First clinical proof-of-concept showing is induced this may lead to poorer healing and in which clinical applications we expect a value of vidual tumors and patients should be selected on need of angiogenesis-stimulating therapies. angiogenesis PET (left) and PET/CT (right) with angiogenesis-inducing therapies, e.g. stem cell our in-house developed PET tracer in a patient with therapy, may be relevant. The hy-pothesis is angiogenesis-PET? basis of this. With angiogenesis-PET, it would be breast cancer (upper panel) and a patient with a currently being tested in an ongoing phase II possible non-invasively to evaluate the individual Taken together, we believe our new angiogenesis neuroendocrine tumor (lower panel). Both tumors clinical trial (Image provided by Bentsen S et al.). Neoangiogenesis, which is the target of our PET patient’s tumor and metastases for level of neoan- PET tracer is broadly applicable in cancer and car- show high uptake of the PET tracer in-dicating tracer, is involved both in cancer and cardiovascu- giogenesis and thereby to select cancer patients diovascular disease as shown in Figure 5. However, induction of angiogenesis. In other patients with Figure 5. How angiogenesis is important both lar disease as well as in other diseases. In tumor likely to be responders to anti-angiogenesis ther- as angiogenesis is also a central element in other same types of tumors no or little angi-ogenesis was in cancer and cardiovascular disease and may growth, the induction of neovessels through apy. Moreover, angiogenesis-PET may be used to disease entities we expect to expand our list of found (images not shown). We hypothesize that be-come key in personalizing angiogenesis- release of vascular endothelial growth factor follow the effect on angiogenesis of the therapy. probably applications in the future. degree of angiogenesis as meas-ured on PET, may modifying therapies.

20 department of clinical physiology, nuclear medicine & pet Pediatric Nuclear Medicine

Head of Pediatric Nuclear Medicine, Consultant Lise Borgwardt

In 2019 we performed more than 3,000 pediatric room and a renography room. PET/MR-scans of medical doctors, PhD students and techni- nuclear medicine investigations. It is a special are performed in the PET-section. In each scan- cians involved in the field. We conduct research focus area for our clinic to perform children ner-room in the children’s section, high quality protocols in children with acute and chronic investigations at the highest level of excellence, projectors are showing films at the ceiling to liver diseases incl. translational piglet studies and at the same time make it a positive experience secure and entertain the child during the scan. and a PhD in the field was defended this year. for both the child and the parents. In the waiting area the children have the oppor- In order to develop this interesting area, we tunity to watch the animated decorations, use have developed protocols in pediatric non-on- This year we have been continuing the cooperation apps or watch films at the tablets giving when cological PET/MRI and also our data from the of the organizational work on preparing our new entering the section or play in the toy corner. pediatric PET/MRI protocol for children with Children’s Hospital Copenhagen. The project is CNS tumors are being analyzed. We started very visionary and contains a large Diagnostic Unit Our multidisciplinary pediatric hematology up artificial intelligence projects in pediatric where Paediatric Nuclear Medicine, among other and oncology conferences are presented as a oncological diseases and a master was defended diagnostic specialties, will be located. We have web-based nuclear medical platform combined this year. In 2019 we continued participating seen a virtual reality presentation of the Diagnostic with videoconference including districts outside in randomized clinical trials for experimental Unit and it will be fantastic new facilities. The Chil- the capital. Our collaborators are very pleased immunotherapy for children with cancer as a dren’s Hospital Copenhagen will be finished 2024. with the possibilities and the advantages in the part of the Nordic Center for these treatments. diagnostic evaluation of the children. We are also part of the EpSSG in the Radiology We already have a children’s section integrated Committee, participating in conducting the new in our department with a children-friendly Research in pediatric nuclear medicine and PET European protocol. PET/128SliceCT, SPECT/CT, EDTA Clearance is necessary, as we have an increasing number

department of clinical physiology, nuclear medicine & pet 23 BørneRiget Children’s Hospital

Head of Pediatric Nuclear Medicine, Consultant Lise Borgwardt

Rigshospitalet is building a Children’s Hospital. in one kingdom, rather than a collection of small lish an Academy where the hospital can share Family them for generations to come. Coordinated pioneering new, more effective working proce- The vision behind the new hospital for children principalities. And lastly, of course, because its professional competencies with educational The goal is to revolutionize the patient’s hospital patient and medicine scanning, electronic medical dures that can be adopted elsewhere. Research. and families is encapsulated in the hospital’s BørneRiget (Children’s Hospital Copenhagen) institutions, research departments and the wider experience before, during and after treatment, records, electronic wayfinding and continual At the new hospital, we will create true synergy Danish name, BørneRiget, which translated is part of Rigshospitalet – known colloquially as business community. We will invent and intro- which also means taking into account the wider monitoring of individual bed locations are just between treatment, research and education; a directly means Children’s Kingdom. The empha- Riget. duce a new continuity of patient care, bringing family experience. In addition to feeling secure, some of the options already included in our hospital where new knowledge about diagnostics sis is on the first part of the name, Children specialists to the patient rather than the other welcome and involved in the treatment process, planning. procedures and treatment is created and shared (Børne), since the overarching theme of the user The vision for BørneRiget is simply to create a way round. We will make the hospital accessible families must help to shape, design and develop a with a view to achieving scientific breakthroughs. experience at the hospital will be the insight that hospital for children and families that sets new to the outside world. In short, we will enhance hospital with a community focus. Effectiveness For this reason, education and research must be an kids will be kids. And, on a more general level, standards in two key areas – patient care and the the quality of Denmark’s best specialized hospital Logistics. Bed days. Incorrect treatment. Naturally, integrated part of day-to-day clinical work. that users, whatever their age, do not stop being interplay between architecture, organization and for children and family members a hundredfold. Technology it would be self-defeating to create a hospital who they are when they step over the threshold operations. The new hospital will accord equal A grand ambition perhaps, so let us begin with Emotional well-being is only part of the picture. project of this caliber without enhancing treatment The Diagnostic Centre within the BørneRiget will of the hospital. The emphasis is also on kingdom focus to treatment, research and training while the three main focus areas: Family, Technology The new hospital complex will implement the effectiveness. A key part of our vision is to revitalize be at an international level, encompassing several (Riget), since the users should find themselves striving to be the best in all three. We will estab- and Effectiveness. highest technological standards – future-proofing and develop the entire Danish health service, inter-disciplinary areas of specialization,

24 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 25 Education

Professor, Consultant Jann Mortensen and Consultant Peter Oturai

The department contributes to the activities of physiology, molecular imaging as well as more The department’s educational activities have been the Faculty of Health Sciences at the University of basic courses in methodology (MR and Kinetics), accredited by the Accreditation of Nuclear Medi- Copenhagen for medical students, human biology all held at our department and arranged by cine Training Centres Committee of the Section students and medicine & technology students our professors and consultants. Furthermore, of Nuclear Medicine of the European Union of in collaboration with DTU in various subjects, we contribute to the specialist education of Medical Specialists (UEMS) and The Danish e.g. physiology, nuclear medicine, and medical physicians from other specialties such as urology, Health Authorities. technology. In addition, regarding undergraduate nephrology, radiology, oncology, hematology, education, nuclear medicine technologist students pulmonology and thoracic surgery. A high number Consultant Peter Oturai is responsible for the and radiography students receive part of their of PhD students are associated with the research postgraduate education of physicians in the education at the department. activities in the department. department. Professor Jann Mortensen, Professor Ian law and Professor Henrik Larsson are respon- As goes for postgraduate education, seven educa- Colleagues and students from Denmark and sible for the undergraduate education of medical tional positions for young physicians training abroad, have visited the department for students in the department. Professor Liselotte to become specialists in clinical physiology and educational and research purposes for periods Højgaard is responsible for under- and postgradu- nuclear medicine are held by our facilities. Other ranging from weeks to months, and we deliver ate education for bioengineers. roles in the specialist education of physicians are training programs to staff from other nuclear related to the dedicated courses in oncology-, medicine and radiological departments in cardiology-, lung-, and endocrinology- patho- Denmark and the Nordic countries.

department of clinical physiology, nuclear medicine & pet 27 Agfa RIS/PACS

Consultant Johan Löfgren

In the beginning of 2018 Rigshospitalet imple- much also to all colleagues for hanging in there between RIS/PACS and EPJ (Sundhedsplatfor- mented, as the last hospital the region, the new and putting extra effort and patience in their men). Unfortunately this integration is far from Agfa RIS/PACS system. A huge project initially everyday work when the system is instable and flawless, which has resulted in excessive extra started in 2009 where the radiology, clinical slow. work for our administrative staff during the last physiology and nuclear medicine departments in year. Region Hovedstaden, after a joint requirements The regional IT department in collaboration with analysis, agreed on shifting to a common RIS/ the RIS/PACS vendor has used large resources Alongside struggling with the system and report- PACS system. trying to fix the problems without any major ing issues, an expert group has evaluated our success. We had hoped for huge improvement vendors next generation RIS/PACS system, actu- Ever since the system was installed, we’ve been with the three major updates planned to be imple- ally the version our region originally purchased having huge problems with performance, stability mented in autumn 2019. Unfortunately only one 10 years ago. The group has tried to find out if and speech recognition. Thank you very much to update was successful. One was postponed and it would fulfill our functional needs of a modern our local system administrators, Maria Pejtersen, the third failed and resulted in major problems RIS/PACS system. At the same time the regional Martin Ravn Jensen, Katrine Cappelen, Mads the subsequent weeks. IT department has looked into the new system’s Fjelbro Klavsen, Alexandra Hercman and Nanna stability and performance. A decision regarding Freja Folkmann helping the department to survive In 2019 Denmark changed the national healthcare the future of RIS/PACS in our region will be taken in this chaotic IT environment and thank you very billing system which also effected the integration in 2020 and we are hoping for a brighter future.

28 department of clinical physiology, nuclear medicine & pet Neuro PET

Consultant Otto Mølby Henriksen and Professor, Consultant Ian Law 1 In the Neuro-PET Group we continuously strive Our Siemens hybrid PET/MR scanner allows a Figure 1. Example of use of the new PET to improve the use and availability of PET and comprehensive structural and functional evalua- radiotracer [18F]FE-PE2I for assessment hybrid imaging in routine clinical brain imaging, tion of brain pathologies within a single imaging uncertain Parkinsonism in a patient and to further explore hybrid imaging of brain session and is not only a powerful research tool with the “Dr. Strangelove syndrome”. physiology in both the diseased and healthy brain. but now also fully in routine clinical investigations The patient seen in the Memory Clinic Collaborating with international and clinical of patients with dementia and brain tumors and had non-fluent aphasia, but not memory complaints, and the so-called “Alien Hand research partners, a number of clinical and basic in increasing use. This also allows us to evaluate syndrome”, also called “Dr. Strangelove science projects explore the use of the most recent the potential of various novel MRI techniques as syndrome” after the movie. It is a category of development in radiopharmaceuticals and MRI. supplements or alternatives to PET in patients conditions in which a person experiences their referred for routine PET/MRI. For radiotherapy limbs acting seemingly on their own, without This year the new PET radiotracer [18F]FE-PE2I planning and the evaluation of recurrent meningi- conscious control over the actions. This for assessment uncertain Parkinsonism was firmly oma we are employing [68Ga]DOTATOC using our patient had left frontal lobe atrophy on MRI, established in clinical routine (Figure 1). The high-resolution research tomograph (HRRT) PET but normal basal ganglia (left image), 2-[18F] glucose analog 2-[18F]Fluoro-2-deoxy-D-glucose scanner, as the growth pattern of meningioma, FDG PET scanning with slight asymmetrical (2-[18F]FDG) showing the functional integrity of and the small margins of the stereotactic radiation metabolic reduction in the left striatum (red the brain remains the backbone of clinical imaging therapy used make a 2 mm resolution desirable. arrow) and in the left frontal lobe (center of dementia and epilepsy and is increasingly being image), and severe asymmetrically reduced [18F]FE-PE2I PET binding in the left striatum used. Our non-2-[18F]FDG radiotracers comprise With the increasing demand of neuro PET exami- (red arrow) with normal conditions on the amino acid analogue [18F]Flouro-Ethyl-Tyros- nations and also increasing analytical complexity the right side (right image). The image 18 ine ([ F]FET) for brain tumors, the somatostatin of in particular PET/MR studies, we are seeking presentation is consistent with atypical 68 II receptor ligand [ Ga]DOTATOC for meningi- to develop and apply post-processing pipelines Parkinsonism found in the neurodegenerative 11 omas, [ C]-PIB for evaluation of cerebral amyloid providing fully automated reports and standard- disease Corticobasal Degeneration (CBD) in in Alzheimer’s disease, and [15O]H2O for quantifi- ized analyses of PET and MRI data supporting which the “Alien Hand syndrome” is a known cation of cerebral blood flow reserve. clinical interpretation and reporting. clinical expression.

department of clinical physiology, nuclear medicine & pet 31 7 Figure 1. Functional imaging when using MRI of muscle tissue during exercise presents the challenge of creating a setup that allows the desired training MR imaging of of muscle groups in a fashion that is safe, respectful of scanning equipment and allows optimal data acquisition. The setup used to study the physiology of the quadriceps muscles during resistance training is muscle function shown here. 8 Figure 2. Bryan Haddock exercising using some of the equipment used in this study.

7 Figure 3. The distribution of muscle activity within Professor, Consultant Henrik BW Larsson muscle groups can be mapped by quantifying changes in MRI R2 relaxation rate values. Here, a subject having performed knee extension exercise with one leg and In patients with neuromuscular pathologies the collaboration with researchers from University of hand grip with one arm is scanned with [18F]FDG evaluation of rehabilitation paradigms can be Southern Denmark, Herlev Hospital and Bispeb- PET/MRI. Measured [18F]FDG uptake and changes very challenging as the normal signaling between jerg Hospital, we have measured that similar in R2 values identify similar distributions of muscle the brain and the muscles is partly or completely responses in muscle tissue can be achieved when activity. disrupted. An important milestone in developing using this technique despite low loads and fewer 7 Figure 4. By applying a compression cuff during successful interventions for these patient groups repetitions. exercise, changes in R2 measured in muscle tissue were is to achieve the ability to detect the stimulation of on average higher and more uniform even though muscle groups in the body and predict whether an Physicist Bryan Haddock, figure 2, completed a the workload on the contracting muscle was reduced intervention will help maintain or even improve PhD thesis in 2019 using these MRI techniques by more than half. Above is a map of R2 changes in muscle function. In 2019, we have worked with to image muscle activity and evaluate differences muscles of the leg after performing repeated one-legged MRI scanning methods that map the distribution between differing exercise strategies known to knee extension exercise lifting a load of 20% subjects of skeletal muscle activation within both large and elicit skeletal muscle hypertrophy. The techniques maximum with the cuff applied. Below is a measure in small muscle groups, in vivo, throughout repeated applied include quantitative mapping of muscle the same subject (opposite leg) when the exercise was performed without the cuff using a load of 50% of the contractions, involving a set-up as shown in figure activation (estimated using R values), blood 2 subject’s maximum. 1. Along with the distribution of activation, we oxygen saturation (assessed via R2* values) along acquire important physiological information with mapping diffusion rates of tissue fluid and 7 Figure 5. Graphs show measures of relative arterial regarding shifts in tissue fluids, blood flow and monitoring changes in blood flow, see figure 3, 4 (A) and venous (B) blood flow in exercising muscle with oxygenation. and 5. the cuff applied (BFR-20) and without (FF-20wm and FF-50) over several sets of knee extension exercise. At Of particular interest, we have worked with Collectively, the use of multimodal MRI to exam- recommended pressures, the cuff reduces blood flow by a special training technique that has proven ine selected peripheral physiological variables 50-60% compared to the same exercise without the cuff effective in helping patient groups regain muscle represents a promising tool not only for decoding (FF-20wm) or the same exercise without the cuff and with a heavier load (FF-50). The augmented stimulation of strength and muscle mass during rehabilitative important mechanisms of adaptation, but also for muscle growth that occurs with the addition of a compres- muscle training. The technique involves applying optimizing the design of effective and personalized sive cuff has been hypothesized to result from blood flow compression during exercise via a cuff in a fashion training strategies for patients with neuromuscu- being reduced to a point where the metabolic demands of similar to when measuring blood pressure. In lar diseases. the active muscle cannot be met, initiating a cascade of alterations in metabolite concentrations and fluid shifts.

32 department of clinical physiology, nuclear medicine & pet PET/MR

1 1 Figure 1. Example of deep learning PET/MRI brain Figure 2. 18F-FDG PET/MRI images from a project attenuation correction. The Deep learning attenuation investigating the diagnostic value of PET/MRI in patients map ‘DeepDixon’ predicted from MRI matches closely the with newly diagnosed vulvar cancer, with special focus reference CT. Training, test and validation was done using on localized spread of the tumour. A) Transverse contrast a total cohort size of 1037 patients. PET bias was below 2% enhanced T1-weighted fat-suppressed Turbo spin echo in any region of the brain. [C Ladefoged et al., submitted] MRI. B) FDG PET. C) PET/MRI fused image.

Physicist Adam Espe Hansen and Consultant Johan Löfgren

PET/MRI offers a unique simultaneous combi- Clinical PET/MRI is undertaken primarily of To further expand the clinical use of PET/MRI, nation of molecular imaging with anatomic and patients with dementia, primarily Alzheimer’s a large number of ongoing clinical research functional MRI. These capabilities are being disease, patients with brain tumors examined studies explore the utilization of PET and MRI exploited in clinical, translational and basic with 18F-FET PET and pediatric patients. Here, the in a synergistic fashion to improve patient research, as well as for clinical examinations. The simultaneous PET and MRI acquisition reduces management. Indications investigated include types of PET/MRI examinations performed at the the overall scan time and provides all indicated lung cancer, head and neck cancer, gyneco- department range from clinical dementia exams imaging within one session. Such a ‘one-stop-shop’ logical cancer (Figure 2), prostate cancer, including static 18F-FDG PET and anatomic MRI examination provides a valuable logistic advantage neuro-oncology, pediatric oncology, and vascu- with a duration of 20 minutes, to dynamic PET for patients and relatives as well as for the diagnostic lar brain diseases. Finally, a number of clinical with kinetic modeling and physiologic MRI meas- reading and minimizes PET/MRI misalignment. In and pre-clinical research studies examine the urements which may last 1-2 hours. In 2019 the 2019 we implemented Artificial Intelligence – based utilization of combined PET and MRI to charac- number of examinations performed was approxi- PET attenuation correction in clinical routine, for terize the biology of disease. mately 800, out of which 70% were clinical. 18F-FDG PET brain examinations (Figure 1).

department of clinical physiology, nuclear medicine & pet 35 Nuclear medicine technologists, radiographers and lab technicians

Chief Nuclear Medicine Technologist Linda M. Kragh

Nuclear medicine technologists, radiographers Thank you to each and every one of you for the and lab technicians are together with medical helpful, professional and dedicated effort. secretaries and physicians crucial for our patient investigations and research. Masterplan In the department we use the lean concept to The Radiochemistry Section have been busy, and adapt the increased number of patient referrals. we have increased the production of Gallium-68 PET/CT scans are used increasingly, and we have Dotatoc and have extended the opening hours of to plan carefully to secure slots for acute patients the department to 6 PM on Tuesdays and 7 PM and for research. We have a new group working on Thursdays to secure that patients can be inves- with a master plan to streamline the exploitation tigated and treated in time. This extension has of our PET/CT scanners. Both nuclear medicine been a challenge to plan, and it has led to a new technologists, physicians, radiochemistry and dynamic in the department. It has after a run in medical secretaries are members of the group, period been evaluated positively. The number of and the whole procedure from production of PET staff in the section has been extended accordingly. tracer to reporting of PET/CT scans are carefully planned. This master plan is a dynamic document, The work environment is in focus, and we have updated after each meeting, chaired by Staff emphasized good manners, a polite, helpful Nuclear Medicine Technologist Maria Pejtersen. and professional attitude with inclusion and Through constant updates and implementation of acceptance. We have tried to reduce procedures the new PET/CT scanner 5 it has been possible to with lifting of heavy patients and stuff, and we reduce the scan time. have installed lifts for patients in several of the scanners. Courses for staff in how to work smarter In May 2019 the old fashioned 99mTc myocardial have been held throughout the year. perfusion SPECT studies were moved from the

36 department of clinical physiology, nuclear medicine & pet Content: Minimum 128 hours on several hospital departments. ECTS: Minimum 20 ECTS points.

Project with communication at the end. Point: Up to the total 40 ECTS.

The tuition should be minimum 40 ECTS, and the puzzle pieces can be put together as desired.

Glostrup Section to Blegdamsvej, where we do the ing a new task can take responsibility for own to develop a new specialist education in clinical cardiac studies for all patients using 82Rubidium progress. Focus has been on theory, patient safety, physiology and nuclear medicine for our nuclear PET scans. our ICT system, and how to perform their investi- medicine technologists and radiographers. The gations. After training the staff nuclear medicine aim of the education is competence development To reduce the number of no-show patients, we technologists have the responsibility for certifying to secure a high professional level in the future contact patients by phone to remind them on their the staff member and it is then documented in D4, to improve patient investigations and support appointment with us, as we previously saw that our document management system. development and innovation in our specialty. some patients either had forgotten or not received At present we have held meetings with all the the invitation letter. Education departments in Denmark in clinical physiology We participate in the pregraduate education of and nuclear medicine, and we collaborate as Professionalism biotechnologists and radiographers. This year shown in the puzzle. We are dedicated to a professional attitude one of the bachelor projects won the Bachelor by continuous education and participation in Prize: “Optimering af 18F-FE-PE2I scanning samt Our Nuclear Medicine Technologist Mia Hjorth relevant courses and national and international undersøgelse af tidspunkt for den optimale speci- Albers is leader of the project. Mia Hjorth Albers symposia, workshop and congresses. We encour- fikke bindingsradio for18 F-FE-PE2I”. and the national group work to describe the age that staff members present a poster or an oral curriculum of the education and plan the anchor- presentation. We have focused on apprenticeships Specialist education for nuclear medicine age of the education in the future. among colleagues and have specific training technologists and radiographers schemes with requirements concerning both We have participated in a project in Region theory and practice, so that staff members learn- Hovedstaden, the Capital Region of Copenhagen,

38 department of clinical physiology, nuclear medicine & pet Medical secretaries

In the department we have highly competent workload. A dedicated thank you to Tina Vikmann medical secretaries important for referral of Nielsen, Gudrun Semitoje, Frederikke Hurup patients, organisation of the flow of patients Henriksen, Pia Kastrup, Marianne Stahlfest, Mette through the department, writing the reports and Fabiansen Larsen, Nina Bjørling, Camilla Kuhre sending them to the clinical departments. They Vildrik Bendtzon and Nanna Folkmann. do a dedicated effort, and we have no waiting lists Our Head Medical Secretary Vibeke Rønn is assis- for patients or reports. The medical secretaries tant to the leadership of the department. master the complicated booking and secure that the waiting lists, the patient control examinations We would like to say a warm thank you to every- and research scans can be done in spite of a high one for the high quality and performance.

Gudrun Semitoje’s 25 years Anniversary September 6th, 2019

40 department of clinical physiology, nuclear medicine & pet

3 Figure 1. Development in 18F, 11C and the total number of productions since 2010.

Cyclotron Section 3 Figure 2. Average received dose per year for employees in the Cyclotron- and Radiochemistry Section since 2010.

3 Figure 3. Development in release of radioactive gas via our new chimney and filter system.

3 Figure 4. Total dose distribution in the neighborhood of the chimney for a total release of 0,55 TBq last year. Values are shown at a height of 20 m above ground level.

Cyclotron Chief Holger J. Jensen and Assistant Cyclotron Chief Jesper Jørgensen

During the last 10 years we have experienced The authorities require the chimney designed, for the machine. Most part of the RF system has a relative stable number of productions at our so no one in the general public can receive a been replaced already and in 2018 we signed two cyclotrons of 1.220±120 productions per radiation dose from our activities higher than new contracts with the external companies year, see figure 1. In 2019 we had in total 1.266 100 µSv/year (or approximately 40 times lower “Wintek” and “Racetrack Microtron Systems AB” successful productions (553 and 713 for our than the average background dose in Denmark). for replacements of the last parts of the RF system Scanditronix MC32 and Siemens RDS Eclipse At figure 4 we show the estimated total dose and other electronic boards respectively. In 2019 cyclotrons respectively) giving an average success distribution from the release last year illustrated these projects were finalized and installed with rate of 99,4±0,5% since 2010. As in the previous for a 400 x 400 meter grid in the neighborhood of success. See figure 5. years we managed to keep the average radiation the chimney. The example is given for a height of dose to the employees in the Cyclotron- and Radi- 20 m, where we have the highest concentrations. In 2019 we received very important spare parts ochemistry Section at a low level, see figure 2. The highest possible dose level is seen to be below for our CTI/Siemens Eclipse cyclotron from John 2 μSv and far from the release limit. Mallard PET Centre in Aberdeen. They decided to Figure 3 shows the development in the controlled shut down their machine, that is almost identical release via our chimney of low radioactive waste During the last few years, we have invested in to our, for a replacement with a GE PETTrace and gas produced in our Cyclotron- and Radiochemis- various upgrade projects for our Scanditronix we got the possibility to get all non-radioactive try Section since 2010. Our permission from the MC32 cyclotron. The machine is unique, and it parts for free. authorities (SIS) allows us to release 10 TBq per is our ambition that the cyclotron should run for year. In 2019 we ended at the very save side with several decades more. One plan during the last a release of only 5,5% of this limit. few years has been to upgrade all electronics

42 department of clinical physiology, nuclear medicine & pet Radiochemistry Section

Chief Radiochemist, Production Manager Jacob Madsen and Chief Radiochemist Nic Gillings

Production for clinical and research PET [68Ga]Ga-OPS202 was produced for a multicenter, Disease is now produced routinely 3 or 4 times investigations in humans randomized, dose-confirmation, factorial phase per week. Optimization of the production allowed II study to evaluate the optimal dose of [68Ga] for a more robust process and more stable radio- Production of [18F]FDG and krypton-81m gener- Ga-0PS202 as a PET imaging agent in subjects chemical yields, and in 2019 151 batches were ators along with [18F]FET, [18F]FLT, [11C]PIB and with gastroenteropancreatic neuroendocrine released for human use. [15O]water continued on a similar level compared tumor (GEP-NET). to previous years. We continued to produce the A system for production of O-15 water developed uPAR imaging agent, [68Ga]Ga-NOTA-AE105 [68Ga]Ga-PSMA-11 was produced as diagnostic by the Danish company MedTrace Pharma A/S and our angiogenesis tracer, [68Ga]Ga-NODA- agent for “The VISION trial”: An international, was installed during the last weeks of 2019. Vali-

GA-E[c(RGDyK)]2. Both are being evaluated in prospective, open label, multicenter, randomized dation and approval for clinical use is anticipated phase II clinical trials. There were more than Phase III study of [177Lu]Lu-PSMA-617 in the in 2020. 1,100 batches released for human use in 2019 treatment of patients with progressive PSMA-posi- comprising of 15 different radiopharmaceuticals tive metastatic castration-resistant prostate cancer (see figure). Production of neuroreceptor PET (mCRPC). radioligands for human use, for various research projects conducted by The Neurobiology Research Neurobiology Unit at Rigshospitalet, continued as in previous Our collaboration with The Neurobiology years. Research Unit, Rigshospitalet and the Department of Drug Design and Pharmacology, Faculty of Radiopharmaceutical development Health and Medical Sciences, University of Copen- hagen continued as in previous years. This work Oncology mainly focuses on development and evaluation of A phase I clinical trial to evaluate 18F-labelled new PET ligands for brain research. Production of active site-inhibited factor VIIa ([18F]ASIS), our a promising synaptic density tracer, [11C]UCB-J, first radiolabeled protein, was completed in 2019 has been set up and validated and an application and the results are under evaluation. This PET for human use was submitted in 2019. tracer binds to tissue factor, which, apart from playing a central role in the coagulation cascade, The dopamine transporter ligand, [18F]FE-PE2I, is up regulated in a number of cancer forms. which is used for the diagnosis of Parkinson’s O-15 water production system

department of clinical physiology, nuclear medicine & pet 45 Radiopharmaceutical Batches Usage/Target 7 [18F]FDG 354 Oncology/glucose metabolism Radiopharmaceuticals produced for human use in 2019 Krypton-81m generator 148 Lung ventilation [11C]PIB 117 Alzheimer's Disease/β-amyloid plaques [68Ga]Ga-DOTATOC 94 Neuroendocrine tumours/somatostatin receptors [68Ga]Ga-NOTA-AE105 60 Oncology/uPAR imaging 11 [ C]SB207145 25 Brain Research/5-HT4 receptors 68 [ Ga]Ga-NODAGA-E[c(RGDyK)]2 77 Oncology/angiogenesis imaging [18F]FE-PE2I 151 Neurology/dopamine transporter ligand [18F]FET 53 Oncology/amino acid transport 11 [ C]Cimbi-36 5 Brain Research/5-HT2A receptors [18F]FLT 6 Oncology/cell proliferation tracer [15O]Water 7 Cerebral blood flow [68Ga]Ga-PSMA-11 21 Oncology/prostate specific membrane antigen ligand [68Ga]Ga-OPS202 17 Neuroendocrine tumors/somatostatin receptors (clinical trial) [18F]ASIS 10 Oncology/tissue factor imaging Total 1,145

Education in radiopharmaceutical chemistry tibody-based positron emission tomography evaluation of PET radioligands for imaging of The teaching program in radiopharmaceutical (PET) imaging biomarkers for immuno-PET the serotonergic system. chemistry led by Associate Professor Matthias and establish a platform for translation into 3 Ida Andersen started a PhD in December 2019 Herth, which was initiated in 2016 at the Faculty of clinical use. which focuses on 18F-labelled compounds tar- Health and Medical Sciences, University of Copen- 3 Klas Bratteby started a PhD project in Janu- geting LAG3 for animal studies. hagen, continued in a similar format in 2019, with ary 2018 which is focused on investigation 3 Sara Lopes van den Broek started her PhD several members of the Radiochemistry Section of 18F-fluorination methods for base sensitive project in February 2019, which focuses on the involved in lecturing and practical exercises. In labelling precursors. One aim of the project development of blood-brain barrier penetrating addition, Matthias Herth supervises a significant is to be able to improve the radiosynthesis of trans-cyclooctene (TCO) modified antibodies number of the PhD students listed below. [18F]FE-PE2I and 18F-labelled tetrazines. Prom- (mAb) for pre-targeted PET imaging within the ising results regarding the optimization of the central nervous system. In vitro characteriza- Radiopharmaceutical research and PhD projects radiochemical yield of [18F]FE-PE2I have been tion and analyses of the TCO-mAb conjugates 3 Troels Elmer Jeppesen is employed as a post- achieved. with 111In- and 18F-labelled tetrazines have doc and works on methods for rapid fluo- 3 Vladimir Shalgunov started as a postdoc in shown promising results and therefore in vivo rine-18 labelling of peptides and labelling of November 2017 and is working on the estab- studies are scheduled in the coming year for optimized ligands for uPAR. lishment of methods for the imaging of brain further evaluation of the TCO-mAbs. 3 Camilla Christensen started her PhD project targets. Particular directions of his work are 3 Rocío García Vázquez started her PhD in 2019. in March 2018 where the focus will be to development of tetrazine-based radioligands She is developing 18F-labelled tetrazines for develop and validate novel radiolabeled an- for pre-targeted PET imaging of the brain and pre-targeted imaging.

46 department of clinical physiology, nuclear medicine & pet Academic and other activities

Andreas Kjær, Professor, Consultant, ERC Anne Kiil Berthelsen, Consultant, is member of the Danish Society of Clinical Physiology and Nuclear to Rigshospitalets Research Strategy Council. Re- ISMRM White Matter Study Group as SMRT rep- working group” under the European Association of advanced grantee, is member of the Oncology International Lymphoma Radiation Oncology Group, Medicine. Member of Regional Working Groups for sponsible for PET/MRI attenuation correction. resentative. Vice Chair in the Local Chapters Com- Nuclear Medicine (EANM), European Association of Committee of the European Association of Nuclear Steering Committee (ILROG), “European Organisa- implementation of clinical guidelines for: lympho- mittee, member of the Global Relation Committee, Neuro- oncology (EANO), and Society of Neuroon- Medicine (EANM), member of the advisory board tion for Research and Treatment of Cancer Lympho- ma, malignant melanoma, lung cancer, cancer of Elisabeth Albrecht-Beste, Clinical Associate Profes- MR Safety Committee and Nominations Committee cology (SNO). Member of the Danish Neurooncology of the European Neuroendocrine Tumor Society ma Group ” (EORTC), the Danish Society of Radiol- unknown primary, and suspicion of severe disease. sor, Consultant, member of Danish Society of Radiol- in International Society for Magnetic Resonance in group (DNOG), responsible for the specialist training (ENETS), national representative of the Europe- ogy, the Danish and the Nordic Society of Gynaeco- Member of National Working Groups for lympho- ogy, chair of post-graduate radiology courses in Den- Medicine (ISMRM)/Section for MR Technologists course in the central nervous system for nuclear an Society for Molecular Imaging (ESMI), board logical Oncology, British institute of Radiology (BIR), ma (Chair of the Diagnostic Imaging Group under mark, chair of post-graduate education committee of (SMRT). Board member of the Danish Society for medicine physicians. member of the Cancer Research Foundation at Billeddiagnostisk udvalg Ukendt Primærtumor Danish Lymphoma Group (DLG)) and pharyngeal/ Danish Society of Radiology, chair of the Regional Ad- Magnetic Resonance, member and service respon- University of Copenhagen, advisory board mem- (DAHANCA), National PET/CT Group, the Danish laryngeal cancer. Member of the National PET/CT visory Board in postgraduate education in radiology sible. Jann Mortensen, Clinical Professor, Consultant, ber of the Avatar Cancer Program, CPMC (Sutter Society of Clinical Oncology, the Danish Society of Group. Board member of DGCG (Danish Gynecologi- and member of the Danish Society of Oncoradiology. is responsible for the specialist course in “Clini- Health), San Francisco. Past President of the Magnetic Imaging, Diagnostic Imaging Group under cal Cancer Group). Henrik B.W. Larsson, MD, DMSc, Consultant, Head cal Respiratory Physiology” for nuclear medicine Scandinavian Society of Clinical Physiology and Danish Lymphoma Group, ERS European Society of Flemming Littrup Andersen, MSc, PhD, Associate of Functional Imaging Unit. Professor in Clinical and physicians and respiratory physicians. Responsible Nuclear Medicine (SSCPNM) and member of the Radiology and Sundhedsstyrelsens Udvalg for Kræft. Birgitte Hanel, Biomedical Scientist, DMSc. Member Professor, is involved in a number of clinical research Comparative Physiology, Institute of Clinical Med- physician for Nuclear Medicine in the Faroe Islands, Scientific Committee of the Danish Cancer Society. of the committee, Dansk Lungefunktions Standard. protocols, supervisor for several PhD, master and icine, The Faculty of Health and Medical Science, member of the steering committee of “Dansk Lunge- Founding Editor-in-Chief of Diagnostics (Basel). Anne-Mette N. Wittekind, MSc. Pharm., Deputy Member of the Spirometry Committee, ERS. Teach- bachelor students and involved in both pre- and post- University of Copenhagen, Denmark, Professor in cancer Gruppe” (Danish Lung Cancer Group), the International associate editor of Editorial board Qualified Person, is member of Dansk Standard. ing in specialist course in “Clinical Respiratory Phys- graduate teaching. Head of the research program Medical Magnetic Resonance Imaging, Norwegian subcommittees for “Dansk Diagnostisk Lungecancer member of Journal of Nuclear Medicine (JNM) and iology” for nuclear medicine physicians and respira- CAAI for Clinically Applied Artificial Intelligence at University of Science and Technology, Norway, Gruppe” (Danish Diagnostic Lung Cancer Group) European Journal of Nuclear Medicine & Molecular Annika Loft Jakobsen, Consultant, MD, PhD, is tory physicians. Teaching in course of spirometry and the department. Member of the HYBRID Network; Responsible for specialist course in tracer kinetic and “Lungecancer Screeningsgruppen” (Screening Imaging (EJNMMI). Leader of projects for devel- involved in a various number of clinical research pro- quality control organized by PLO. Board member of a collaboration for research and training of young theory, math and statistic for nuclear medicine physi- of Lung Cancer Group), member of the steering opment of theranostics for aggressive cancer and tocols, teaching at national and international courses the Foundation of Biomedical Laboratory Scientists. researchers in the field of hybrid imaging, funded as cians. Responsible for specialist course in functional committee and the quality subcommittee for creat- for project of hyperPET, funded by the Innovation pre- and postgraduate for medical doctors, tech- a Marie Sklodowska-Curie Innovative Training Net- imaging (MRI, PET-MRI, UL) for nuclear medicine ing Danish reference values for lung function, and Fund Denmark. Coordinator of an H2020 project on nologists, radiographers and nurses and is invited Bryan Haddock, MPE, MSC, Member of both the work under EU Horizon 2020. physicians, Management board of EU COST Action member of the steering committee of the Danish click-chemistry for PET. Head of the Cluster for Mo- speaker at national and international meetings and Danish Society for Clinical Physiology and Nuclear (BM1103): “Arterial Spin Labelling in Dementia”, spirometry course. lecular Imaging and Director of the PhD Program congresses. She is supervisor and opponent for sev- Medicine (DSKFNM) and the Danish Society for Helle Hjorth Johannesen, Consultant, is member Steering committee of the 7 Tesla project, Copenha- for Medical & Molecular Imaging at the Faculty of eral PhD students and responsible for the specialist Medical Physics (DSMF). Supervisor for several mas- of Danish Society of Radiology, member of Danish gen, Denmark. Member of the Danish Multiple Scle- Johan Löfgren, Consultant, teaches at specialist Health and Medical Sciences, University of Copen- course in oncology for nuclear medicine physicians. ter- and bachelor students. Society of Oncoradiology, member of Danish Society rosis Research Council. courses for oncologists, endocrinologists, radiolo- hagen. Co-chair of the Lundbeck Foundation Dan- She is member of the “European Organization for Re- of Medical Magnetic Resonans Imaging and Danish gists and nuclear medicine specialists. Member of the ish American Research Exchange (DARE) Program. search and Treatment of Cancer” (EORTC). Member Claes Nøhr Ladefoged, Postdoc, MSc, PhD, co-su- Society for Good Clinical Practice. Ian Law, Professor, Consultant, is Chair of the Diagnostic Imaging Group under Danish Lymphoma Member of the Industrial Researcher Committee, of the Oncology Committee of the European Associ- pervisor for PhD and MSc students in the depart- Neuroimaging Comittee, European Association of Group. Involved in clinical research protocols with Innovation Fund Denmark. Member of the Academy ation of Nuclear Medicine (EANM) and member of ment. Co-head of research group Clinically Applied Helle Juhl Simonsen, Research MR Technologist, Nuclear Medicine (EANM), Member of the “PET special focus on PET/MRI and is an invited speaker at of Technical Sciences (ATV). BIR, Danish Society of Oncological Radiology and Artificial Intelligence (CAAI) and academic secretary Biomedical Laboratory Scientist. Board member in Response Assessment in Neurooncology (RANO) national and international meetings and congresses.

48 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 49 Academic and other activities

Kim Francis Andersen, Consultant, is member of member of the Process Group for the development postgraduate teaching. Member of the European As- Physiology and Nuclear Medicine (DSKFNM) and Ronan M.G. Berg, MD, PhD, Staff Specialist and European and International organizations for Med- the Board of Danish Sarcoma Group (DSG). He is of the Children’s Hospital at Rigshospitalet. Involved sociation of Nuclear Medicine (EANM), European So- member of the Danish Epilepsy Surgery Team. He is Associate Professor of respiratory physiology at the ical Physics (EFOMP and IOMP), assessor for EFO- involved in various clinical research protocols. He in clinical research protocols, supervisor for PhD stu- ciety of Hybrid Imaging (ESHI), the Danish Society of co-supervisor of two PhD student and teaches at PhD University of Copenhagen, Visiting Professor at the MP’s Examination Board (EBB), member of an IAEA teaches at specialist courses for medical doctors and dents, teaching at national and international courses Clinical Physiology and Nuclear Medicine (DSKFNM) courses as well as pregraduate courses for Medicine University of South Wales, UK, scientific co-editor at advisory group concerned with QA/QC of non-im- is supervisor for students at the Medicine and Tech- pre- and postgraduate for medical doctors, and in- and the Danish Society of Clinical Oncology. Affiliated and Technology Bioengineers. the journal Physiology News (London, UK). Member aging nuclear medicine equipment and member of nology programme (Biomedical Engineering), Tech- vited speaker at national and international meetings to the Centre of Excellence for Personalized Medicine of several scientific societies including the Physiolog- ICRP Task Group 117 for radiation protection in PET nical University of Denmark (DTU). and congresses. of Infectious Complications in Immune Deficiency Peter Oturai, Consultant, is responsible for the post- ical Society (UK) and the Danish Society of Medical and PET/CT. He is member of Sundhedsfagligt Råd (PERSIMUNE). Work package leader in the HYBRID graduate education of physicians in the department. Philosophy, Ethics, and Methodology, of which he i Klinisk Fysiologi og Nuklearmedicin in the Capital Linda Kragh, Chief Nuclear Medicine Technologist, Liselotte Højgaard, Professor, Head of Department, Network; a collaboration for research and training of He is head of the Doctors Clinical Physiology and is board member in the latter. He has previously Region, (the Specialty Advisory Committee (SFR) in is member of Sundhedsfagligt Råd i Klinisk Fysiologi member of the Board, Die Robert Bosch Stiftung, young researchers in the field of hybrid imaging, fund- Nuclear Medicine (CPNM) Training Committee affil- received the prestigious Pfizer Prize from the Physio- Clinical Physiology and Nuclear Medicine) and exter- og Nuklearmedicin i Region H, SFR, (the Speciality Germany. Member of the Board of Directors, The ed as a Marie Sklodowska-Curie Innovative Training iated to DSKFNM. He is responsible for the specialist logical Society for his contributions to the physiologi- nal lecturer at University of Copenhagen. Advisory Committee in Clinicial Physiology and Novo Nordisk Foundation. She represents the Univer- Network under EU Horizon 2020. Since June 2018 course in Endocrine Pathophysiology for CPNM phy- cal sciences. He teaches physiology, nuclear medicine Nuclear Medicine in the Capital Region), member sity of Copenhagen, Rigshospitalet in the Medicine holding a joined position as Senior Clinical Lecturer sicians in Denmark. and medical ethics at both pre- and postgraduate Thomas Levin Klausen, Chief Physicist, MSc, Spe- of the DRG Committee of DSKFNM, and member of and Technology Bioengineer program, the Technical and honorary Consultant at the PET Centre, Guy’s & levels, and handles scientific supervision on bache- cialist Medical Physicist, Chair of Danish Society for Uddannelsesudvalget på Radiografuddannelsen at University of Denmark (DTU), where she is also St Thomas Hospital, Kings College London in UK. Rasmus Sejersten Ripa, Consultant, DMSc, Super- lor, master, and PhD levels both in Denmark and in Medical Physics Educational Council, member of the Metropol (the Speciality Council for the Education of adj. professor. Elected member of the Royal Danish visor for several PhD students. Member of the Danish the UK. Danish Society for Medical Physics (DSMF) and the Radiographers at Metropol). Member of “Forum for Acade- my of Sciences and Letters, elected member Maria Helene Pejtersen, Nuclear Medicine Technol- Health Authority’s Committee for Heart Disease. Danish Society of Clinical Physiology and Nuclear uddannelse” på Rigshospitalet. of ATV, “the Danish Academy of Technical Scienc- ogist, is member of the Symposiagroup for Technolo- Board member of the Society for Theoretical and Sune Høgild Keller, Computer Scientist, PhD, is Medicine (DSKFNM). Responsible Physicist for Nu- es”, member of the Olav Thon Foundation, Science gists at Rigshospitalet. Applied Therapy and member of American Society of involved in various clinical and preclinical research clear Medicine at the Faroe Islands. Lise Borgwardt, Consultant, Chief of Pediatric Nu- Advisory Board, member of the Board of the Crown Nuclear Cardiology. protocols and scientific development in PET/CT, clear Medicine at Rigshospitalet, Senior Advisor of Prince Frederik and Crown Princess Mary’s Foun- Nic Gillings, MPhil, PhD, Chief Radiochemist, Qual- PET/MR and neuro-PET (HRRT). He teaches at a Ulrik B. Andersen, Consultant, Co-supervisor for the Paediatric Committee under EANM, Scientific dation and member of the Board of Arvid Nilsson’s ified Person (QP) is vice chair of the EANM Radiop- Robin de Nijs, MSc, PDEng, PhD, Specialist Med- variety of courses for medical doctors, PhD students, PhD students in the department. Member of Euro- Committee member of the EANM, boardmember of Foundation and Tagea Brandt’s prize. harmacy Committee, member of the Society of Radi- ical Physicist, is member of the Danish Society for technologists and MSc students. He is supervisor for pean Society of Hypertension and acknowledged hy- DAPHO, member of Radiology Committee EpSSG, opharmaceutical Sciences and member of the Royal Medical Physics and lecturer at the Technical Uni- students at the Medicine and Technology program pertension specialist by this society. Responsible for member of NM Committee SIOPEN, member of the Louise Alslev, Consultant, teaches at the Bachelor´s Society of Chemistry. He also acts as coordinator for versity of Denmark, Copenhagen University and (Biomedical Engineering), Technical University of the specialist course in cardiovascular circulation for Paediatric Imaging Harmonization Group EANM/ Degree Program in Radiography at the University the joint supplier audit program for all manufactur- for the association of physics teachers. Supervisor Denmark (DTU) and co-supervises PhD students in nuclear medicine physicians in Denmark. Member of SNM, member of the Tumourboard for Paediatric College Copenhagen (KP). ers of PET radiopharmaceuticals in Denmark and for Danish and international students in a.o. Medi- biomedical engineering and computer science. the Danish Society of Clinical Physiology and Nuclear Solid Tumours at Rigshospitalet, Chair of Danish Southern Sweden. cine & Technology and Medical Physics. Associated Medicine, Danish Society of Cardiology and Danish Association of Paediatric Nuclear Medicine, Chair Malene Fischer, Associate Professor of Research, physicist for the SPECT brain scan section of the Søren Holm, Senior Physicist, is chair of the EANM Society of Diagnostic Ultrasound. of the Paediatric Focus Group at the Department of Consultant, is supervisor for several PhD, master Otto Mølby Henriksen, Consultant, PhD, is member Neurobiology Research Unit at Copenhagen Uni- Radiation Protection committee. He is a delegate for Clinical Physiology, Nuclear Medicine and PET and and bachelor students and involved in both pre- and of the DRG Committee in Danish Society for Clinical versity Hospital. the Danish Medical Physics Society (DSMF) to the

50 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 51 Equipment 2019

Chief Physicist Thomas Levin Klausen

Equipment Product Purchase year Equipment Product Purchase year Mediso Nucline X-Ring 2003 Siemens mMR 2011 PET/MR scanner Mie-Scintron 2004 GE SPINlab MR Hyperpolarizer 2014 Mediso TH45 2007 Jaeger Masterscreen w/bodybox 2005 Gamma cameras Mediso N-TH45-D 2008 Lung function Jæger Masterscreen w/bodybox 2019 DDD SoloMobile 2012 Jaeger PFT pro w/bodybox 2007/13 DDD NephroCam System 2016 GE Lunar Prodigy 2004 Mediso Nucline X-Ring-R/HR 2009 GE Lunar Prodigy 2005 SPECT-cameras DXA scanner Symbia Evon 2017 GE Lunar Prodigy 2011 GE Infinia Hawkeye 2004 GE Lunar iDXA 2014 Siemens SymbiaT2 2006 WBC w/Nal counting chamber 1977 Whole body counter Philips, Precedence 16-slice CT 2008 WBC w/plast counting chamber 1978 SPECT/CT cameras GE Discovery 670 2010 Scanditronix 32 MeV 1991 Cyclotrons Siemens Symbia 16-slice CT 2011 RDS Eclipse cyclotron, CTI 2005 Siemens Symbia Intevo Bold 16 slice CT 2017 Provivo/ ADAC mobile gamma camera 1990 PET scanner HRRT Siemens/CTI 2007 Siemens Micro-PET Focus 120 2006 Siemens Biograph TrueV 64-slice CT 2009 Phosphor Imager Perkin Elmer cyclone 2007 Siemens Vision (64) 2019 At Cluster for Bruker preclinical MRI PharmaScan 7T 2013 Molecular Imaging, Siemens Vision (64) 2019 Siemens preclinical PET/CT Inveon 2013 PET/CT scanner Panum Siemens mCT-S (128) 2013 PX Inc. preclinical RT X-RAD 320 2013 Siemens mCT-S (64) 2016 Mediso nanoScan SPECT/CT 2015

department of clinical physiology, nuclear medicine & pet 53 Studies 2019

CNS and peripheral nervous system Myocardial perf. scintigr. gated, 99mTc-MIBI 43 Bone and joint Other diagnostic procedures 15 123 99m 99m Regional cerebral blood flow, DIAMOX, O-H2O 8 Myocardial I- MIBG, sympaticus activity 3 Bone scintigraphy, Tc-HDP, regional, static 39 Aprotinin scintigraphy Tc- aprotinin 1 Regional cerebral metabolism, 18F-FDG 1,754 Myocardial scintigraphy, 99mTc-PYP 12 Bone scintigraphy, 99mTc-HDP, 2 phased 47 PET scanning, 18F-FDG 6,812 Regional cerebral receptor, 11C-PIB 207 Myocardial calcium score 733 Bone scintigraphy, 99mTc-HDP, whole body, static 1,005 PET tumor scanning, 68Ga-Dotatoc 234 Regional cerebral receptor, 18F-FET 470 Tilt table test 287 Bone scintigraphy, 99mTc-HDP, SPECT 798 PET tumor scanning, 68Ga-PSMA 45 Regional cerebral receptor, 18F-FE2PI 452 Analysis of heart rate variability 287 Bone PET scanning 18F-NaF 3 PET tumor scanning, 64Cu-Dotatate 610 Regional cerebral blood flow,99m Tc- HMPAO, pharm. prov. 16 PET myocardial metabolism, 18F-FDG 145 Osteodens. dual X-ray absorptiometri (DXA), columna lumb. 4,943 White blood cell scintigraphy, 99mTc-white blood cell 17 Regional cerebral blood flow,99m Tc- HMPAO 15 PET myocardial perfusion, 82Rb, rest 843 Osteodens. dual X-ray absorptiometri (DXA), lat.spine 173 White blood cell scintigraphy, 99mTc-white blood cell, SPECT 10 Regional cerebral receptor, 18F-Florbetapir + FLP 17 PET myocardial perfusion, 82Rb, pharmacological stress 771 Osteodens. dual X-ray absorptiometri (DXA), radius 182 Whole body, contamination measurement 56 Regional cerebral receptor, 18F-FLT 8 Total 4,692 Osteodensitometri, dual X-ray absorptiometri collum fem. 6,954 Image fusion (PET, SPECT, MRI, CT or planar) 14,576 Regional cerebral receptor, 68Ga-Dotatoc 74 DXA, body composition 823 CT head/neck SPECT/CT 321 CT scanning of cerebrum 435 Peripheral vessels MR scanning columna 125 CT wb SPET/CT 416 MR scanning of cerebrum with and without contrast 2,560 Doppler ultrasound of the carotides 4,002 MR scanning columna thoracalis 30 CT thorax SPECT/CT 567 MR scanning of hippocampus (MR-HCV) 403 Systolic blood pressure, fingers 1 MR scanning columna lumbalis 4 CT pelvis SPECT/CT 148 Cisternography 99mT c-DTPA 3 Systolic blood pressure, ancle and toes 369 Total 15,126 CT abdomen SPECT/CT 315 Total 6,422 Systolic blood pressure, ancle-brachial index after treadmill 131 CT lower and upper extremities SPECT/CT 24 24 hours blood pressure measurement 248 CT wb PET/CT with contrast 6,440 Doppler ultrasound of abdominal vessels 386 Endocrine organs Respiratory organs 99m CT wb PET/CT 1,693 99m Thyroid scintigraphy, Tc-Pertechnetat 1,056 Lung function test, whole body plethysmography 2,717 Isolated limb perfusion leakage monitoring, Tc-erythrocyt 2 Thyroid scintigraphy, 123I-Iodide 79 MR wb PET/MR 28 Lung function test, whole body plethysmography w/reversibility 384 Total 5,139 Thyroid +ultrasound 1,134 Second opinions external PET, PET/CT, SPECT/CT, CT and MR investigations 2,192 Lung function test, spirometry 824 Gastric intestinal tract, liver, biliary tract and pancreas Thyroid +fine needle aspiration biopsy 142 Extra tumor delineation 268 Lung function test, spirometry w/reversibility 246 11 Salivary gland scintigraphy 99mTc-Pertechnetat 18 Iodine uptake test, 131I-Iodide 50 Other investigations, incl. C-different tracers (NRU) 313 Lung function test, diffusion capacity (CO) 4,098 Biliary tract scintigraphy, 99mTc-Mebrofenin 58 Parathyroid scintigraphy, 99mTc-Stamisis, SPECT 78 Supplementary/repeated imaging 2192 Lung function test, diffusion capacity (NO/CO) 92 Bleeding scintigraphy (abdomen) 99mTc-erytrocytter 3 Adrenal marrow scintigraphy, 123I-MIBG 26 Total 37,278 Max. insp. abd. exspir. muscle pressure 3 Doppler ultrasound of splanchnic blood flow 177 99m 382 Scintigraphy after Lu- Dotatate therapy 325 Lung perfusion scintigraphy, Tc-MAA 1 Meckels diverticle scintigraphy 99m 3 Total 2,890 Radiotherapy Lung perfusion scintigraphy, SPECT, Tc-MAA 453 131 81m Total 464 Treatment with I, benign thyroid 99 Lung ventilation scintigraphy, Kr-gas 50 177 81m Isotope treatment with Lu-Dotatate 172 Lung ventilation scintigraphy, regional, Kr-gas 266 Kidneys and urinary tract Blood and lymph system 223 51 Isotope treatment with Ra-Dichlorid 83 Lung ventilation scintigraphy, SPECT, 81mKr-gas 394 Glomerular filtration,51 Cr-EDTA 305 Erythrocyt red blood celle survival, Cr-erythrocytter 2 99m 51 Total 354 Lung ventilation scintigraphy, SPECT 99mTc-Technegas 58 Glomerular filtration,99m TC-DTPA 2,182 Erythrocyt volume, Tc-and Cr erythrocytter 23 125 Mucociliary clearance, 99mTc-Venticolloid 50 Renal scintigraphy, 99mTc-DMSA 5 Plasma volume, I-HSA 17 99m CT thorax PET/CT breathhold 20 Renography, 99mTc-MAG, diuresis 25 Sentinel node scintigr. tumor drainage, Tc-Nanocolloid 239 In vitro analyses 99m PET thorax PET/CT breathhold 18 Renography, 99mTc-MAG 3, ACE-inhibitor 142 Sentinel node scintigr. tumor drainage, SPECT Tc-Nanocolloid 202 Affinity studies 405 99m Total 9,674 Renography, 99mTc-MAG 3 2,224 Sentinel node scintigr. tumor drainage, head/neck SPECT, Tc-Nanocolloid 5 Flow cytometry analyses 69,674 99m Doppler ultrasound of renal blood flow 365 Peritumoral injection of Tc-Nanocolloid for sentinel node 623 Gene expression analyses 5,740 99m Heart and cardiovascular system Ultrasound kidneys 362 Spleen scintigraphy, Tc-erythrocyte, heated 10 Immunohistochemistry 2,158 Isotope cardiography, LVEF, 99mTc-HSA 1,518 MR kidneys 80 Total 1,121 Plasma and protein analyses 25,021 Myocardial perf. scintigr. gated, 99mTc-MIBI, pharmacol. stress 50 Total 5,139 Total 102,998

54 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 55 Studies 2019 Finance

Animal studies 99mTc SPECT 18 111In-Tetrazine 48 Turnover 64Cu-TDM1 12 Dogs AI-18F-NOTA-AE105 36 HyperPET (RGD/13Cpyruvat) 1 AI-18F-XX-AE105 8 Bioluminescens (luminol) 60 350 Rats Bioluminescens (luciferin) 1,229 15O 4 Fluorescens (Cy5.5) 101 300 18F-FDG 210 Fluorescens (ICG) 40 64Cu-DOTATATE 67 Fluorescens (ICG-AE105) 313 250 68Ga-RGD 182 Fluorescens (IRDye800-AE105) 74 82 Rubidium 4 MR 1,332 200 99mTc SPECT 61 CT images for fusion 902 224Ra-Ca-CO3 18 Ultrasound 3 150 Bioluminescens (luciferin) 2 Photothermal therapy 68 MR 279 Radiotherapy, externally 3,097 100 CT images for fusion 437 Radionuclide therapy (α and β emitters) 507

Ultrasound 216 Krone points in mio DKK Rabits 50 Mice 18F-FDG 96 18F-FDG 221 18F-FET 1 0 18F-FHBG 5 18F-NaF 23 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 18F-tetrazine 160 64 Cu-DOTATATE 61 Year 18F-tryptophan 4 68Ga-RGD 11 64 CuCl2 14 82Rubidium 29 The increase in activities measured in krone point* rose from 114.4 mio DKK in 64 Cu-anti-CD8a 49 CT images for fusion 177 2008 to 336.8 mio DKK in 2019. 64Cu-DOTATATE 226 64 Cu-anti-CD4 66 Pigs * Krone point: Price for each patient investigation multiplied with number of 64 Cu-micelles 64 HyperPET (18F-FDG/13Cpyruvat) - investigations, summarized for all patient studies performed during the year. 64Cu-tetrazine 8 MR - 68Ga-XX-AE105 7 - 68Ga-xx 4 Total 10,731 89Zr-anti-CD3 40 Balance 2019 89Zr-anti-PDL1 32 89 Zr-Herceptin 9 Expenditure (DKK mio ) 95 89Zr-xx 96 Total number of studies 196,889 Receipts 13

56 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 57 Publications

Theses Shaker S,Imaging methods (Billeddiagnostiske newborn infants with quantitative rCBF measure- Jensen BL, Holst JJ, Bülow J. Extracellular Fluid noma of the esophagogastric junction. Abdominal patients with non-ischaemic systolic heart fail- metoder). Medicinsk Kompendium, 2019, 19 ud- ments using 15O-water PET. J Cereb Blood Flow Volume Expansion Uncovers a Natriuretic Action radiology (New York). 2019;44(3):836-844. ure: a cross-sectional study using Rubidium-82 Sabrina Khan, MD, MRI investigations of migraine gave, 799-804. Metab. 2019;39(5):782-793. of GLP-1: A Functional GLP-1-Renal Axis in Man.J Berg RMG, Asghar MS. Luxury perfusion in patients positron emission tomography/computed without aura in an experimental human model. Andreassen M, Ilett E, Wiese D, Slater EP, Klose M, Clin Endocrinol Metab. 2019;104(7):2509-2519. with sepsis? Crit Care Med. 2019;47;e533. tomography. Eur Heart J Cardiovasc Imaging. Defended February 8,2019, University of Copen- Patents Hansen CP, Gercke N, Langer SW, Kjaer A, Mau- Asmar M, Asmar A, Simonsen L, Dela F, Holst JJ, Binderup T, Duivenvoorden R, Fay F, van Leent MMT, 2019;20(2):233-240. hagen. rer E, Federspiel B, Kann PH, Bartsch DK, Knigge Bülow J. GIP-induced vasodilation in human adi- Malkus J, Baxter S, Ishino S, Zhao Y, Sanchez-Gay- Byrne C, Kjaer A, Hasbak P. The Authors’ Reply. JACC Nelly Richard, M.Sc., Neurophysiological Correlates Kjaer A (with co-inventors). 177Lu-labeled active site U. Surgical Management, Preoperative Tumor pose tissue involves capillary recruitment. Endocr tan B, Teunissen AJP, Frederico YCA, Tang J, Car- Cardiovasc Imaging. 2019;12(5):946-947. of Cognitive Decline. Defended November 18, inhibited factor VII. US-16461723. November 28, Localization, and Histopathology of 80 Patients Connect. 2019;8(6):806-813. lucci G, Lyashchenko S, Calcagno C, Karakatsanis Byrne C, Kjaer A, Wissenberg M, Hurry PK, Schme- 2019, University of Copenhagen. 2019. Operated on for Insulinoma. J Clin Endocrinol Me- Bærentzen S, Casado-Sainz A, Lange D, Shalgunov V, N, Soultanidis G, Senders ML, Robson PM, Mani V, des A, Forman JL, HasbakP. Dose-Dependent Ef- Nielsen, J. PhD thesis. Pediatric Liver Disease. Ex- Kjaer A (with co-inventors). PET tracer for imaging tab. 2019;104(12):6129-6138. Tejada IM, Xiong M, L’Estrade ET, Edgar FG, Lee H, Ramachandran S, Lobatto ME, Hutten BA, Grana- fect of Caffeine on Adenosine-Induced Myocardial ploring methods for assessment of the course of of neuroendocrine tumors. US-16454631. October Aneheim E, Palm S, Jensen H, Ekberg C, Albertsson Herth MM, Palner M. The Chemogenetic Receptor da JF, Reiner T, Swirski FK, Nahrendorf M, Kjaer Stress Perfusion in Rubidium-82 Positron-Emission disease. Defended June 24, 2019, University of 24, 2019. P, Lindegren S. Towards elucidating the radi- Ligand Clozapine N-Oxide Induces in vivo Neu- A, Fisher EA, Fayad ZA, Pérez-Medina C, Mulder Tomography/Computed Tomography. JACC Cardi- Copenhagen. Kjaer A (with co-inventors). uPAR targeting peptide ochemistry of astatine – Behavior in chloroform. roreceptor Occupancy and Reduces Striatal Gluta- WJM. Imaging-assisted nanoimmunotherapy ovasc Imaging. 2019;12(6):1102-1103. Byrne C. Ph.D thesis. Myocardial perfusion in pa- for use in peroperative optical imaging of invasive Scientific Reports. 2019;9;15900. mate Levels. Front Neurosci. 2019;13:187. for atherosclerosis in multiple species. Sci Transl Byrne C, Pareek M, Kjaer A, Hasbak P. Caffeine and tients with non-ischemic systolic heart failure and cancer. US-16142977. May 2, 2019. Arngrim N, Hougaard A, Schytz HW, Vestergaard Bashir A, Brennum J, Broholm H, Law I. The diag- Med. 2019;11(506). myocardial perfusion: a clinical perspective. Eur different additive factors: A cross-sectional study Kjaer A (with co-inventors). Quantitative PET im- MB, Britze J, Amin FM, Olsen KS, Larsson HB, nostic accuracy of detecting malignant transfor- Blond MB, Schnurr TM, Rosenkilde M, Quist JS, Heart J Cardiovasc Imaging. 2019;20(7):763-764. using rubidium-82 PET/CT. Defended January 19, aging of tissue factor expression using 18F-labeled Olesen J, Ashina M. Effect of hypoxia on BOLD mation of low-grade glioma using O-(2-[ 18F]fluo- Gram AS, Reichkendler MH, Auerbach PL, Nordby Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg 2019, University of Copenhagen. active site inhibited factor VII. US-16070073. Jan- fMRI response and total cerebral blood flow in roethyl)-l-tyrosine positron emission tomography: P, Skovgaard LT, Ribel-Madsen R, Justesen JM, S, Ahmadzadehfar H, Grana CM, Zandee WT, uary 17, 2019. migraine with aura patients. J Cereb Blood Flow a retrospective study. Journal of Neurosurgery. Kilpeläinen TO, Ploug T, Stallknecht BM, Hansen Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver Books Metab. 2019;39(4):680-689. 2019;130(2):451-464. T. PPARG Pro12Ala Ala carriers exhibit greater A, Frilling A, Gritti S, Arveschoug AK, Meirovitz Publications Asferg C, Chen X, Pehrson S, Jacobsen PK. Catheter Bashir A, Jacobsen M, Henriksen OM, Broholm H, improvements in peripheral insulin sensitivity in A, Knigge U, Sorbye H. Peptide receptor radionu- Arreola M, Bianchi C, Dickson, JC, Fuglsang S, Holm ablation of atypical flutter using new 3-dimen- Urup T, Grunnet K, Andrée Larsen V, Møller S, response to 12 weeks of aerobic exercise training. clide therapy in gastroenteropancreatic NEN G3: S, Izaki M, Kappadath CS, Mawlawi O, de Nijs R, Agn M, Munck Af Rosenschöld P, Puonti O, Lunde- sional electroanatomic mapping software focusing Skjøth-Rasmussen J, Skovgaard Poulsen H, Law I. Physiol Genomics. 2019;1;51(6):254-260. a multicenter cohort study. Endocr Relat Cancer. Oliveira MA, Poli GL, Reichkendler MH, Robilot- mann MJ, Mancini L, Papadaki A, Thust S, Ash- on areas of conduction block. HeartRhythm case Recurrent glioblastoma versus late posttreatment Bloomquist K, Adamsen L, Hayes SC, Lillelund C, An- 2019;26:227-239. ta CC, Søndergaard LR, Teles Garcez A. SPECT/ burner J, Law I, Van Leemput K. A modality-adap- reports. 2019;5(4):225-228. changes: diagnostic accuracy of O-(2-[18F]fluo- dersen C, Christensen B, Oturai P, Ejlertsen B, Tux- Carlsen EA, Knigge U. Peptid-receptor radionuklid CT Atlas of Quality Control and Image Artefacts, tive method for segmenting brain tumors and Asferg CL, Andersen UB, Linneberg A, Goetze JP, roethyl)-L-tyrosine positron emission tomography en MK, Møller T. Heavy-load resistance exercise terapi til patienter med neuroendokrine neoplas- IAEA Human Health Series No. 36, IAEA, Vienna, organs-at-risk in radiation therapy planning. Med Holst JJ, Jeppesen JL. Copeptin, a surrogate mark- (18F-FET PET). Neuro Oncol. 2019;21:1595- during chemotherapy in physically inactive breast ma. Best Practice. 2019:1-3. 2019:127pp. ISBN 978–92–0–103919–4. Image Anal. 2019;54:220-237. er for arginine vasopressin secretion, is positively 1606. cancer survivors at risk for lymphedema: a rand- Christensen A, Juhl K, Kiss K, Lelkaitis G, Char- Al-Karagholi MA, Ghanizada H, Hansen JM, associated with glucagon. Diabetic Medicine. Bebbington NA, Haddock BT, Bertilsson H, Hip- omized trial. Acta Oncol. 2019;58(12):1667-1675. abi BW, Mortensen J, Kjaer A, von Buchwald Skovgaard LT, Olesen J, Larsson HBW, Amin FM, 2019;36(11):1408-1411. peläinen E, Husby EM, Tunninen VI & Söderberg Byrne C, Hasbak P, Kjaer A, Thune JJ, Køber L. Im- C. Near-infrared fluorescence imaging improves Book Chapters Ashina M. Levcromakalim, an Adenosine Triphos- Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, M. A Nordic survey of CT doses in hybrid PET/ paired myocardial perfusion is associated with in- the nodal yield in neck dissection in oral cavity Hostrup M. Lung function assessment (Lungefunk- phate-Sensitive Potassium Channel Opener, Goetze JP, Jeppesen JL. Serum proatrial natriuret- CT and SPECT/CT examinations. EJNMMI Phys. creasing end-systolic- and end-diastolic volumes in cancer - A randomized study. Eur J Surg Oncol. tionsundersøgelse). In: Medicinsk Kompendium, Dilates Extracerebral but not Cerebral Arteries. icpeptide concentrations during oral glucose-in- 2019;6:24. patients with non-ischemic systolic heart failure: 2019;45(11):2151-2158. 2019, 19 udgave., side 791-804. Headache. 2019;59(9):1468-1480. duced acute hyperinsulinemia in lean and obese Belmouhand M, Löfgren J, Johannesen HH, Baeks- a cross-sectional study using Rubidium-82 PET/ Christensen CE, Amin FM, Younis S, Lindberg U, de Hostrup M. Anatomy & physiology (Anatomi og Andersen JB, Lindberg U, Olesen OV, Benoit D, Lade- men. Peptides.2019;111:98-102. gaard L, Gutte H, Tariq K o.a. Early response CT. BMC Cardiovasc Disord. 2019;19(1):68. Koning P, Petersen ET, Paulson OB, Larsson HBW, fysiologi). In: Medicinsk Kompendium, 2019, 19 foged CN, Larsson HB, Højgaard L, Greisen G, Law Asmar A, Cramon PK, Simonsen L, Asmar M, So- evaluation of neoadjuvant therapy with PET/MRI Byrne C, Hasbak P, Kjaer A, Thune JJ, Køber L. My- Ashina M. Sildenafil and calcitonin gene-related udgave., side 784-789. I. Hybrid PET/MRI imaging in healthy unsedated rensen CM, Madsbad S, Moro C, Hartmann B, to predict resectability in patients with adenocarci- ocardial perfusion during atrial fibrillation in peptide dilate intradural arteries: A 3T MR angi-

58 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 59 Publications

ography study in healthy volunteers. Cephalalgia. bertsson P, Lahoutte T, Caveliers V, Lindegren S, chotic-naïve schizophrenia patients. Psychol Med. Frederiksen KS, Madsen K, Andersen BB, Beyer borg J, Atharovski K, Christensen T, Holmvang Haddock BT, Larsson H, Andersen U. Authors’ Reply. 2019;39(2):264-273. D’Huyvetter M, Labeling of anti-HER2. nanobodies 2019;49(16):2754-2763. N, Garde E, Høgh P, Waldemar G, Hasselbalch L, Engstrøm T, Ripa RS, Kjaer A. Early risk strat- J. Am. Soc. Nephrol. 2019;30:711. Christensen CE, Younis S, Lindberg U, Boer VO, de with astatine-211: Optimization and the effect of Edem PE, Sinnes JP, Pektor S, Bausbacher N, Ros- SG, Law I.Moderate- to high-intensity exercise ification using Rubidium-82 positron emission Hagedorn A, Snoer A, Jensen R, Haddock B, Barloese Koning P, Petersen ET, Paulson OB, Larsson HBW, different coupling reagents on their in vivo behav- sin R, Yazdani A, Miederer M, Kjar A, Valliant does not modify cortical β-amyloid in Alzheimer’s tomography in STEMI patients. J Nucl Cardi- M. The spectrum of cluster headache: A case re- Amin FM, Ashina M. Ultra-high field MR angiogra- iour. Mol Pharmaceutics, 2019;16:3524-3533. JF, Robillard MS, Rösch F, Herth MM. Evalua- disease. Alzheimers Dement (N Y). 2019;5:208- ol. 2019;26(2):471-482. port of 4600 attacks. Cephalalgia. 2019;39:1134- phy in human migraine models: a 3.0 T/7.0 T com- Denk C, Wilkovitsch M, Aneheim E, Herth M, tion of the inverse electron demand Diels-Alder 215. Göransson C, Ahtarovski KA, Kyhl K, Lønborg J, Nep- 42. parison study. J Headache Pain. 2019;6;20(1):48. Jensen H, Lindegren S, Mikula H. Multifunctional reaction in rats using a scandium-44-labelled Frøding LP, Zobbe V, Fokdal LU, Niemann ICS, per-Christensen L, Bertelsen L o.a. Assessment of Håkansson KEJ, Goossens EAC, Trompet S, van da Cunha-Bang S, Ettrup A, Mc Mahon B, Skibsted clickable reagents for rapid bioorthogonal astat- tetrazine for pretargeted PET imaging. EJNMMI Nøtrup TJ, Kristensen E, Christiansen AP, Loft A, the myocardial area at risk: comparing T2-weight- Ingen E, de Vries MR, van der Kwast RVCT, Ripa AP, Schain M, Lehel S, Dyssegaard A, Jørgensen ination and radio‐crosslinking. ChemPlusChem. Res. 2019;9(1):49. Schnack TH. Workup, treatment and follow-up of ed cardiovascular magnetic resonance imaging RS, Kastrup J, Hohensinner PJ, Kaun C, Wojta J, LM, Møller K, Gillings N, Svarer C, Knudsen GM. 2019;84:775-778. Egelund J, Nyberg M, Mandrup CM, Abdulla J, vulva cancer. Ugeskr Laeger. 2019;181(34). with contrast-enhanced cine (CE-SSFP) imaging-a Böhringer S, Le ​Cessie S, Jukema JW, Quax PHA, Measuring endogenous changes in serotonergic Deshmukh AS, Peijs L, Beaudry JL, Jespersen NZ, Stallknecht B, Bangsbo J, Hellsten Y, Larsson HBW. Fuglø-Mortensen R, Lange P, Mortensen J. Inhalator- DANAMI3 substudy. European heart journal cardi- Nossent AY. ​Genetic associations and regulation of neurotransmission with [11C]Cimbi-36 positron Nielsen CH, Ma T, Brunner AD, Larsen TJ, Bayar- Cardiac perfusion and function after high-intensity er og inhalationsteknik ved behandling af astma og ovascular Imaging. 2019;20(3):361-366. expression indicate an independent role for 14q32 emission tomography in humans. Transl Psychia- ri-Olmos R, Prabhakar BS, Helgstrand C, Severin- exercise training in late premenopausal and recent kronisk obstruktiv lungesygdom. Ugeskr Laeger. Griem-Krey N, Klein AB, Herth MM, Wellendorph snoRNAs in human cardiovascular disease. Cardio- try. 2019;11;9(1):134. sen MCK, Holst B, Kjaer A, Tang-Christensen M, postmenopausal women: an MRI study. J Appl 2019;12;(33):181 P. Autoradiography as a Simple and Powerful vasc Res. 2019;115:1519-1532. Dahl RH, Berg RMG, Taudorf S, Bailey DM, Lundby Sanfridson A, Garred P, Privé GG, Pedersen BK, Physiol. 2019;126(5):1272-1280. Galldiks N, Langen KJ, Albert NL, Chamberlain M, Method for Visualization and Characterization of Hallqvist A, Bergmark K, Bäck T, Andersson H, C, Christensen M, Larsen FS, Møller K. Transcere- Gerhart-Hines Z, Nielsen S, Drucker DJ, Mann Eriksen N, Pakkenberg B, Rostrup E, Okonkwo DO, Soffietti R, Kim MM, Law I, Le Rhun E, Chang S, Pharmacological Targets, JoVE, 2019;145:e58879 Dahm-Kähler P, Johansson M, Lindegren S, Jensen bral exchange kinetics of large neutral amino acids M, Scheele C. Proteomics-Based Comparative Mathern B, Shutter LA, Strong AJ, Woitzik J, Pahl Schwarting J, Combs SE, Preusser M, Forsyth P, Grøndahl V, Binderup T, Langer SW, Petersen RH, H, Jacobsson L, Hultborn R, Palm S, Albertsson P. during acute inspiratory hypoxia in humans. Scand Mapping of the Secretomes of Human Brown and C, Dreier JP, Martus P, Lauritzen MJ, Fabricius M, Pope W, Weller M, Tonn JC. PET Imaging in Pa- Nielsen K, Kjaer A, Federspiel B, Knigge U. Charac- Intraperitoneal alpha-emitting radio immunother- J Clin Lab Invest. 2019;79(8):595-600. White Adipocytes Reveals EPDR1 as a Novel Ba- Hartings JA. Neurostereologic Lesion Volumes and tients with Brain Metastasis - Report of the RANO/ teristics of 252 patients with bronchopulmonary apy with Astatine-211 in relapsed ovarian cancer; Deen M, Hougaard A, Hansen HD, Svarer C, Eiberg tokine. Cell Metab. 2019;30(5):963-975. Spreading Depolarizations in Severe Traumatic PET Group. Neuro Oncol. 2019;21:585-595. neuroendocrine tumours treated at the Copen- long-term follow-up with individual absorbed dose H, Lehel S o.a. Migraine is associated with high Diemar SS, Sejling A-S, Eiken P, Suetta C, Jørgensen Brain Injury Patients: A Pilot Study. Neurocrit Gbyl K, Rostrup E, Raghava JM, Carlsen JF, Schmidt hagen NET Centre of Excellence. Lung Cancer. estimations. J Nucl Med. 2019;60(8):1073-1079.

brain 5-HT levels as indexed by 5-HT4 receptor NR, Andersen NB. Hyponatremia and metabolic Care. 2019;30(3):557-568. LS, Lindberg U, Ashraf A, Jørgensen MB, Larsson 2019;132:141-149. Hansen AE, Valladares A, Beyer T, Boellard R, binding. Cephalalgia. 2019;39(4):526-532. bone disease in patients with epilepsy: A cross-sec- Eriksen N, Rostrup E, Fabricius M, Scheel M, HBW, Rosenberg R, Videbech P. Cortical thickness Gudbergsson JM, Kostrikov S, Johnsen KB, Fliedner Chalampalakis Z, Comtat C, Ahangari S, Dalto- Deis T, Balling L, Boesgaard S, Rossing K, Schou tional study. The Bone. 2019;123:67-75. Major S, Winkler MKL, Bohner G, Santos E, following electroconvulsive therapy in patients FP, Stolberg CB, Humle N, Hansen AE, Kristensen so L, Koole M, Mackewn J, Marsden P, Nuyts J, M, Oturai P, Wolsk E, Gustafsson F. Relation Duez L, Tankisi H, Hansen PO, Sidenius P, Sabers A, Sakowitz OW, Kola V, Reiffurth C, Hartings JA, with depression: a longitudinal MRI study. Acta BW, Christiansen G, Kjaer A, Andresen TL, Duroux Padormo F, Peeters R, Poth S, Solari E, Rausch I. between invasive hemodynamics and measured Pinborg LH, Fabricius M, Vajkoczy P, Woitzik J, Martus P, Lauritzen M, Psychiatr Scand. 2019;140(3):205-216. M. A tumorsphere model of glioblastoma multi- Clinically Valuable Quality Control for PET/MRI glomerular filtration rate by51 Cr-EDTA clearance Rásonyi G, Rubboli G, Pedersen B, Leffers AM, Uldall Pakkenberg B, Dreier JP. Early focal brain inju- Ghanizada H, Al-Karagholi MA, Arngrim N, forme with intratumoral heterogeneity for quan- Systems: Consensus Recommendation From the in advanced heart failure. Scand J Clin Lab Invest. P, Jespersen B, Brennum J, ry after subarachnoid hemorrhage correlates Ghanizada M, Larsson HBW, Amin FM, Ashina titative analysis of cellular migration and drug HYBRID Consortium. Frontiers in Physiology. 2019;79:194-201. Henriksen OM, Fuglsang-Frederiksen A, Beniczky with spreading depolarizations. Neurology. M. Effect of pituitary adenylate cyclase-activat- response. Exp Cell Res. 2019;379(1):73-82. 2019;36-150. Dejanovic D, Amtoft AG, Sørensen JB, Pøhl M. S. Electromagnetic source imaging in presurgical 2019;22;92(4):e326-e341. ing polypeptide-27 on cerebral hemodynamics Haddock B, Fan AP, Jørgensen NR, Suetta C, Gold Hansen HD, Constantinescu CC, Barret O, Herth 18F-FDG PET/CT Findings in Disseminated Gen- workup of patients with epilepsy: A prospective Eriksson R, Broberg BV, Ishøy PL, Bak N, Andersen in healthy volunteers: A 3T MRI study. Peptides. GE, Kogan F. Kinetic [18F]-Fluoride of the Knee in MM, Magnussen JH, Lehel S, Dyssegaard A, Co- ital Herpes in an Immunocompetent Patient with study. Neurology. 2019;92:e576-e586. UB, Jørgensen NR, Knop FK, Ebdrup BH. Bone 2019;121:170134. Normal Volunteers. Clin. Nucl. Med. 2019;44:377- lomb J, Billard T, Zimmer L, Tamagnan G, Knudsen Anaplastic Lymphoma Kinase Rearranged Ad- Ebdrup BH, Axelsen MC, Bak N, Fagerlund B, Oranje Status in Obese, Non-diabetic, Antipsychotic-Treat- Ghotbi AA, Clemmensen A, Kyhl K, Follin B, Hasbak 385. GM. Evaluation of [18 F]2FP3 in pigs and non-hu- vanced Nonsmall Cell Lung Cancer. Clin Nucl Med. B, Raghava JM, Nielsen MØ, Rostrup E, Hansen ed Patients, and Effects of the Glucagon-Like P, Engstrøm T, Ripa RS, Kjaer A. Rubidium-82 PET Haddock B, Fan AP, Uhlrich SD, Jørgensen NR, Suet- man primates. Journal of Labelled Compounds 2019;44(5):e351-e352. LK, Glenthøj BY. Accuracy of diagnostic classifi- Peptide-1 Receptor Agonist Exenatide on Bone imaging is feasible in a rat myocardial infarction ta C, Gold GE, Kogan F. Assessment of acute bone and Radiopharmaceuticals. 2019;62(1):34-42. Dekempeneer Y, Bäck T, Aneheim E, Jensen H, cation algorithms using cognitive-, electrophys- Turnover Markers and Bone Mineral Density. Front model. J Nucl Cardiol. 2019;26(3):798-809. loading in humans using [18F]NaF PET/MRI. Eur. Haugaard CF, Agander TK, Lelkaitis G, Andersen Puttemans J, Xavier C, Keyaerts M, Palm S, Al- iological-, and neuroanatomical data in antipsy- Psychiatry. 2019;9:781. Ghotbi AA, Hasbak P, Nepper-Christensen L, Løn- J. Nucl. Med. Mol. Imaging. 2019;46:2452-63. KF, Andreasen S, Wessel I. Salivary gland carci-

60 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 61 Publications

nomas with unusual presentations. Acta Oncol. Jessen K, Rostrup E, Mandl RCW, Nielsen MØ, Bak Kandler K, Nilsson JC, Oturai P, Jensen ME, Møller new BJ, Schjöth-Frydendahl C, Kjaer A, Nielsen nen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, son TG, Knudsen GM. Herth MM. Development 89 13 2019;58(3):382-384. N, Fagerlund B, Glenthøj BY, Ebdrup BH. Cortical CH, Clemmesen JO, Arendrup HC, Steinbrüchel CH. Site-specifically labeled Zr-DFO-trastu- Zhang X, Malloy CR, Rizi R. Hyperpolarized C and Evaluation of Two Potential 5-HT7Receptor Henriksen OM, Kruuse C, Olesen J, Jensen LT, Lars- structures and their clinical correlates in antipsy- DA. Higher arterial pressure during cardiopulmo- zumab improves immuno-reactivity and tumor MRI: Path to Clinical Translation in Oncology. Ne- PET Tracers: [18F]ENL09 and [18F]ENL10. ACS son HBW, Birk S, Hansen JM, Wienecke T, Rostrup chotic-naïve schizophrenia patients before and af- nary bypass may not reduce the risk of acute kid- uptake for immuno-PET in a subcutaneous oplasia. 2019;21(1):1-16. Chemical Neuroscience. 2019;10;9:3961-3968. E. Sources of variability of resting cerebral blood ter 6 weeks of dopamine D2/3 receptor antagonist ney injury. J Cardiothorac Surg. 2019;14:107. HER2-positive xenograft mouse model. Theranos- Kyhl K, Ahtarovski KA, Nepper-Christensen L, Ek- Ladefoged CN, Marner L, Hindsholm A, Law I, Hø- flow in healthy subjects: a study using 133Xe treatment. Psychol Med. 2019;49(5):754-763. Khan S, Amin FM, Christensen CE, Ghanizada H, tics. 2019;9(15):4409-4420. ström K, Ghotbi AA, Schoos M o.a. Complete jgaard L, Andersen FL. Deep Learning Based Atten- SPECT measurements. Journal of Cerebral Blood Johansen A, Holm S, Dall B, Keller S, Kristensen JL, Younis S, Olinger ACR, de Koning PJH, Larsson Kristensen LK, Fröhlich C, Christensen C, Meland- Revascularization Versus Culprit Lesion Only in uation Correction of PET/MRI in Pediatric Brain Flow and Metabolism. 2013;33:787-92. Knudsen GM, Hansen HD. Human biodistribution HBW, Ashina M. Meningeal contribution to mi- er MC, Poulsen TT, Galler GR, Lantto J, Horak Patients With ST-Segment Elevation Myocardial Tumor Patients: Evaluation in a Clinical Setting. + Herth MM, Knudsen GM. Application of advanced and radiation dosimetry of the 5-HT2A receptor graine pain: a magnetic resonance study. Brain ID, Kragh M, Nielsen CH, Kjaer A. CD4 and Infarction and Multivessel Disease: A DAN- Front Neurosci. 2019;12:1005. brain positron emission tomography-based mo- agonist Cimbi-36 labeled with carbon-11 in two 2019;142(1):93-102. CD8a+ PET imaging predicts response to novel AMI-3-PRIMULTI Cardiac Magnetic Resonance Lagström RMB, Østerbye NN, Henriksen OM, Høgh lecular imaging for a biological framework in positions. EJNMMI Res. 2019;9:71-8. Khan S, Amin FM, Fliedner FP, Christensen CE, Tol- PD-1 checkpoint inhibitor: studies of Sym021 Substudy. JACC: Cardiovascular Interventions. P. Hashimoto’s encephalopathy: Follow-up data neurodegenerative proteinopathies. Alzheimer’s & Juhl K, Christensen A, Rubek N, Karnov KKS, von nai D, Younis S, Olinger ACR Birgens H, Daldrup- in syngeneic mouse cancer models. Theranos- 2019;22;12(8):721-730. from neuropsychology, lumbar puncture, and dementia. 2019;11:327-332. Buchwald C, Kjaer A. Improved surgical resection Link H, Kjaer A, Larsson HBW, Lindberg U, Ashina tics. 2019;9(26):8221-8238. L’Estrade ET, Edgar FG, Xiong M, Shalgunov V, Bae- FDG-PET. Clin Case Rep. 2019;7:1750-1753. Horwitz A, Klemp M, Horwitz H, Thomsen MD, of metastatic pancreatic cancer using uPAR tar- M. Investigation macrophage-mediated inflamma- Kristensen TD, Mandl RCW, Raghava JM, Jessen K, rentzen SL, Erlandsson M, Ohlsson TG, Palner M, Langer N H, Langer SW, Johannesen HH, Hansen AE, Rostrup E, Mortensen EL, Osler M, Lauritzen M, geted in vivo fluorescent guidance: comparison tion in migraine using ultrasmall superparamag- Jepsen JRM, Fagerlund B, Glenthøj LB, Wenneberg Knudsen GM, Herth MM. Synthesis, Radiolabe- Costa J, Klausen TL, Forman J, Olin A, Rasmussen Benedek K. Brain Responses to Passive Sensory with traditional white light surgery. Oncotarget. netic iron oxide-enhanced 3 T magnetic resonance C, Krakauer K, Pantelis C, Nordentoft M, Glenthøj ling, In vitro and In vivo Evaluation of [18F]ENL30 SH, Sørensen JB, Löfgren J, Kjaer A, Fischer BM.

Stimulation Correlate With Intelligence. Front Ag- 2019;10(59):6308-6316. imaging. Cephalalgia 2019;39(11):1407-1420. BY, Ebdrup BH. Widespread higher fractional ani- – A Potential PET Radiotracer for the 5-HT7 Recep- Very Early Response Evaluation by PET/MR in Pa- ing Neurosci. 2019;11:201. Jürgens M, Schou M, Hasbak P, Kjaer A, Wolsk E, Kjaer A. Diagnostics Receives First Impact Factor. Di- sotropy associates to better cognitive functions in tor; ACS Omega. 2019;4:7344-7353. tients with Lung Cancer – Timing and Feasibility. Jensen MH, Bak N, Rostrup E, Nielsen MØ, Pantelis Zerahn B, Wiberg M, Brandt NH, Gæde PH, Ross- agnostics (Basel). 2019;9(2). individuals at ultra-high risk for psychosis. Human L’Estrade ET, Hansen HD, Falk-Petersen C, Haugaard Diagnostics. 2019;9(1):35. C, Glenthøj BY, Ebdrup BH, Fagerlund B. The im- ing P, Faber J, Inzucchi S, Gustafsson F, Kistorp Knudsen A, Kristoffersen US, Panum I, Hansen YB, Brain Mapping. 2019;40(18):5185-5201. A, Krey NG, Jung S, Lüddens H, Schirmeister T, Laursen AH, Elming MB, Ripa RS, Hasbak P, Kjaer A, pact of schizophrenia and intelligence on the rela- CM. Design of a randomised controlled trial of Skottrup PD, Hasbak P, Kjaer A, Lebech AM. Cor- Kristiansen JF, Perch M, Iversen M, Krakauer M, Dyssegaard A, Knudsen GM, Herth MM, Wellen- Køber L, Marott JL, Thune JJ, Hutchings M. Rubid- tionship between age and brain volume. Schizophr the effects of empagliflozin on myocardial perfu- onary artery calcium and intima-media thickness Mortensen J. Lobar Quantification by Ventilation/ dorph P, Frølund B. Synthesis and Pharmacological ium-82 positron emission tomography for detec- Res Cogn. 2019;15:1-6. sion, function and metabolism in type 2 diabetes are associated with level of cytomegalovirus Perfusion SPECT/CT in Patients with Severe Evaluation of [11C]4-Methoxy-N-[2-(thiophene- tion of acute doxorubicin-induced cardiac effects Jeppesen TE, Kristensen LK, Nielsen CH, Petersen patients at high cardiovascular risk (the SIMPLE immunoglobulin G in HIV-infected patients. HIV Emphysema Undergoing Lung Volume Reduc- 2-yl)imidazo[1,2-a]pyridine-3-yl]benzamide as a in lymphoma patients. Journal of nuclear cardiol- LC, Kristensen JB, Behrens C, Madsen J, Kjaer A. trial). BMJ Open. 2019;9(11):e029098. Med. 2019;20(1):60-62. tion with Endobronchial Valves. Respiration. Brain Penetrant PET Ligand selective for the d-Sub- ogy: official publication of the American Society of Oxime Coupling of Active Site Inhibited Factor Kahr Rasmussen N, Andersen TT, Carlsen J, Øster- Krabbe S, Helweg-Larsen J, Loft A, Jacobsen S. Mul- 2019;98(3):230-238. unit-Containing g-Aminobutyric Acid Type A Re- Nuclear Cardiology. 2019;1-10. Seven with a Nonvolatile, Water-Soluble Fluo- gaard ML, Konge L, Albrecht-Beste E, Nielsen MB. tifocal vertebral sclerosing bone changes and soft Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, ceptors; ACS Omega, 2019;4:8846-8851. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, rine-18 Labeled Aldehyde. Bioconjugate Chem. Simulation-Based Training of Ultrasound-Guided tissue masses caused by Hodgkin’s lymphoma in a Url C, Riechelmann H, Sprinzl GM, Thomé C, Tre- L’Éstrade ET, Petersen IN, Xxiong M, Hogendorf AS, Galldiks N, la Fougère C, Langen KJ, Lopci E, Lowe 2019;30:775-784. Procedures in Radiology - A Systematic Review. patient with systemic lupus erythematosus: a case glia G, Kjaer A, Fraedrich G, Virgolini IJ. 68Ga-DO- Hogendorf A, Kristensen JL, Kjaer A, Bojarski AJ, V, McConathy J, Quick HH, Sattler B, Schuster DM, Jessen K, Mandl RCW, Fagerlund B, Bojesen KB, Ultraschall Med. 2019;40(5):584-602. doi: report. Scand J Rheumatol. 2019;48:77-78. TATOC PET/CT in the localization of head and Erlandsson M, Ohlsson T, Knudsen GM, Herth Tonn JC, Weller M. Joint EANM/EANO/RANO Raghava JM, Obaid HG, Jensen MB, Johansen 10.1055/a-0896-2714. Krarup MMK, Nygård L, Vogelius IR, Andersen FL, neck paraganglioma compared with 18F-DOPA MM. Radiolabeling and in vivo evaluation of [11C] practice guidelines/SNMMI procedure standards LB, Nielsen MØ, Pantelis C, Rostrup E, Glenthøj Kaltoft NS, Marner L, Larsen VA, Hasselbalch Cook G, Goh V, Fischer BM. PET/CT and 123I-MIBG SPECT/CT. Nucl Med AGH-44: a potential lead structure to develop a for imaging of gliomas using PET with radiola- BY, Ebdrup BH. Patterns of Cortical Structures SG, Law I, Henriksen OM. Hybrid FDG PET/MRI Heterogeneity in tumours: Validating the use of Biol. 2019;71:47-53. positron emission tomography radioligand for belled amino acids and [18F]FDG: version 1.0. Eur and Cognition in Antipsychotic-Naïve Patients vs. FDG PET and CT in patients with suspected radiomic features on (18)F-FDG Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, the 5-HT7 receptor. J Radioanal Nucl Chem. J Nucl Med Mol Imaging. 2019;46:540-557. With First-Episode Schizophrenia: A Partial Least dementia - A comparison of diagnostic yield and PET/CT scans of lung cancer patients as a prognos- Bankson JA, Brindle K, Cunningham CH, Gallagh- 2019;322(2):847-851. Legind CS, Broberg BV, Brouwer R, Mandl RCW, Squares Correlation Analysis. Biol Psychiatry Cogn propagated influence on clinical diagnosis and pa- tic tool. Radiother Oncol. 2019;13;144:72-78. er FA, Keshari KR, Kjaer A, Laustsen C, Mankoff L’Estrade ET, Xiong M, Shalgunov V, Edgar FG, Volk Ebdrup BH, Anhøj SJ, Jensen MH, Hilker R, Neurosci Neuroimaging. 2019;4(5):444-453. tient management. PLoS One. 2019;14:e0216409. Kristensen LK, Christensen C, Jensen MM, Ag- DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ro- B, Baerentzen SL, Palner M, Erlandsson M, Ohls- Fagerlund B, Hulshoff Pol HE, Glenthøj BY,

62 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 63 Publications

Rostrup E. Heritability of Cerebral Blood Flow for prediction of tumour recurrence in patients Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen Nielsen J, Nerup N, Møller S, de Nijs R, Rasmussen A, Jacobs AH, Bottlaender M, Brooks D, Carroll 32 study: Electrochemotherapy for recurrent and the Correlation to Schizophrenia Spec- with glioblastoma. Eur J Nucl Med Mol Imaging. AK, Hodgson D, Eich HT, Dieckmann K, Qi SN, A, Bo Svendsen L, Kjaer MS, Brix Christensen V, MA, Chalon S, Gee G, Gerhard A, Halldin C, Her- mucosal head and neck cancer. Head and Neck. trum Disorders: A Pseudo-continuous Arterial 2019;46(3):603-613. Yahalom J, Specht L. The Optimal Use of Imaging Borgwardt L. Minimally invasive assessment of he- holz K, Herth MM, Hinz R, Knudsen GM, Kuhnast 2019;41(2):329-339. Spin Labeling Twin Study. Schizophr Bull. Madsen CV, Granqvist H, Petersen JH, Rasmussen in Radiation Therapy for Lymphoma: Guidelines patic function in children with indocyanine green B, López-Picón F, Moresco RM, Pappata S, Rinne Prabhakaran J, DeLorenzo C, Zanderigo F, Knudsen 2019;45(6):1231-1241. ÅK, Lund AM, Oturai P, Sørensen SS, Feldt-Ras- from the International Lymphoma Radiation On- elimination: a validation study. Scand J Gastroen- JO, Rodriguez-Vieitez E, Santiago-Ribeiro MJ, GM, Gillings N, Pratap M, Jorgenson MJ, Daunais Legind CS, Broberg BV, Mandl RCW, Brouwer R, An- mussen U. Age-related renal function decline in cology Group (ILROG). Int J Radiat Oncol Biol terol. 2019;54(4):485-491. Turkheimer FE, Van Laere K, Varrone A, Vercouil- J, Kaplan JR, Parsey RV, Mann JJ, Kumar D. In høj SJ, Hilker R, Jensen MH, McGuire P, Pol HH, Fabry disease patients on enzyme replacement Phys. 2019;104(3):501-512. Nielsen, J, Christensen VB, Borgwardt L, Rasmussen lie J, Winkeler A. Application of advanced brain vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR ag- Fagerlund B, Rostrup E, Glenthøj BY. Heritability therapy: a longitudinal cohort study. Nephrol Mortensen J, Berg RMG. Lung scintigraphy in COPD. A, Østrup O, Kjaer MS. positron emission tomography–based molecular onist radiotracer in nonhuman primates. J Pharm of cerebral glutamate levels and their associa- Dial Transplant. 2019;34:1525-1533. 2018 Semin Nucl Med. 2019;49;16-21. Prognostic molecular markers in pediatric liver imaging for a biological framework in neurodegen- Pharm Sci. 2019;22:352-364. tion with schizophrenia spectrum disorders: a Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Munck af Rosenschold P, Law I, Engelholm S, Engel- disease – Are there any? Biochim Biophys Acta Mol erative proteinopathies; Alzheimer’s & Dementia: Puig O, Vestergaard MB, Lindberg U, Hansen AE, 1[H]-spectroscopy twin study. Neuropsychophar- Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, holm SA, Muhic A, Lundemann MJ, Roed H, Grun- Basis Dis. 2019;1865(3):577-586. Diagnosis, Assessment & Disease Monitoring. Ulrich A, Andersen FL, Johannesen HH, Rostrup macology. 2019;44(3):581-589. Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen net K, Skovgaard Poulsen H. Influence of volumet- Nissen A, Marstrand S, Skov-Jeppesen K, Bremholm 2019;11:327-332. E, Law I, Larsson HB, Henriksen OM. Phase Li D, Mikela Vilmun B, Frederik Carlsen J, Albrecht- GM. Psychedelic effects of psilocybin correlate ric modulated arc therapy and FET-PET scanning L, Hornum M, Andersen UB, Holst JJ, Rosen- Petersen IN, Madsen J, Poulie CBM, Kjaer A, contrast mapping MRI measurements of global Beste E, Ammitzbøl Lauridsen C, Bachmann Niels- with serotonin 2A receptor occupancy and plas- on treatment outcomes for glioblastoma patients. kilde MM, Hartmann B. A Pilot Study Showing Herth MM; One-Step Synthesis of N-Succinim- cerebral blood flow across different perfusion en M, Lindskov Hansen K. The Performance of ma psilocin levels. Neuropsychopharmacology. Radiother Oncol. 2019;130:149-155. Acute Inhibitory Effect of GLP-1 on the Bone idyl-4-[18F]Fluorobenzoate ([18F]SFB). Molecules. states - A direct comparison with 15O-H2O Deep Learning Algorithms on Automatic Pulmo- 2019;44(7):1328-1334. Mygind ND, Pena A, Mide Michelsen M, Ali Qayyum Resorption Marker CTX in Humans. JBMR PLUS 2019;24:3436-3443. positron emission tomography using a hybrid nary Nodule Detection and Classification Tested Madsen MK, Fisher PM, Burmester D, Dyssegaard A, A, Frestad D, Emil Christensen T, Ali Ghotbi A, 2019;3:e10209. Petersen N, Knudsen AD, Mocroft A, Kirkegaard-Klit- PET/MR system. J Cereb Blood Flow Metab. on Different Datasets That Are Not Derived from Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Hasbak P, Kjaer A, Vejlstrup N, Gustafsson I, Riis Nøhr A, Gram SB, Charabi B, Tvedskov JF, Wessel I, bo D, Arici E, Lundgren J, Benfield T, Oturai P, 2019;9(12):2368-2378. LIDC-IDRI: A Systematic Review. Diagnostics (Ba- Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen Hansen P, Steen Hansen H, Prescott E, Kastrup Friborg J, Håkansson K, von Nordestgaard BG, Feldt-Rasmussen B, Nielsen SD, Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius sel). 2019;9(4). GM. Correction: Psychedelic effects of psilocybin J. Myocardial first pass perfusion assessed by car- Buchwald C, Fischer BM, Rasmussen JH. PET/ Ryom L. Prevalence of impaired renal function in IR, Johannesen HH, Fischer BM, Bentzen SM, Ludvigsen TP, Pedersen SF, Vegge A, Ripa RS, Johan- correlate with serotonin 2A receptor occupancy diac magnetic resonance and coronary microvas- CT prior to salvage surgery in recurrent head and virologically suppressed people living with HIV Specht L, Kristensen CA, von Buchwald C, Wessel nesen HH, Hansen AE, Löfgren J, Schumacher-Pe- and plasma psilocin levels. Neuropsychopharma- cular dysfunction in women with angina and no neck squamous cell carcinoma. Eur Arch Otorhi- compared with controls: the Copenhagen Comor- I, Friborg J. Intratumor heterogeneity of PD-L1 tersen C, Kirk RK, Pedersen HD, Christoffersen BØ, cology. 2019;44(7):1336-1337. obstructive coronary artery disease. Scand J Clin nolaryngol. 2019;276(10):2895-2902. bidity in HIV Infection (COCOMO) study. HIV expression in head and neck squamous cell carci- Ørbæk M, Forman JL, Klausen TL, Olsen LH, Kjaer Marner L, Nysom K, Sehested A, Borgwardt L, Lab Invest. 2019;79(4):238-246. Olin A, Krogager L, Rasmussen JH, Andersen FL, Med. 2019;20(10):639-647. noma. Br J Cancer. 2019;120(10):1003-1006. A. F-FDG PET/MR-imaging in a Göttingen Minipig Mathiasen R, Henriksen OM, Lundemann M, Naimi RM, Hvistendahl M, Enevoldsen LH, Madsen Specht L, Beyer T, Kjaer A, Fischer BM, Hansen Petersen RJ, Nielsen NS, Johannesen HH, Hansen Rasmussen T, Kjaer A, Hasbak P. Stomach interfer- model of atherosclerosis: Correlations with histol- Munck Af Rosenschöld P, Thomsen C, Bøgeskov L, JL, Fuglsang S, Poulsen SS, Kissow H, Pedersen AE. Preparing data for multiparametric PET/MR AE, Jespersen S, Arnbjerg CJ, Löfgren J, Kjaer ence in 82Rb-PET myocardial perfusion imaging. J ogy and quantitative gene expression. Atheroscle- Skjøth-Rasmussen J, Juhler M, Kruse A, Broholm J, Nerup N, Ambrus R, Achiam MP, Svendsen LB, imaging: Influence of PET point spread function MS, Clausen MR, Kjaer A, Nielsen SD, Fischer BM. Nucl Cardiol. 2019;26(6):1934-1942. rosis. 2019;285:55-63. H, Scheie D, Lauritsen T, Forman JL, Wehner PS, Holst JJ, Hartmann B, Hansen SH, Dragsted LO, modelling and EPI distortion correction on the PET/DW-MRI for evaluating treatment in chronic Reuter S, Lindgaard D, Laursen C, Fischer BM, Clem- Lund N, Petersen A, Snoer A, Jensen RH, Barloese Højgaard L, Law I. Early Postoperative (18)F-FET Steensberg A, Mouritzen U, Hansen MB, Jeppesen spatial correlation of [18F]FDG-PET and diffu- hepatitis C patients. Am J Nucl Med Mol Imaging. entsen PF, Bodtger U. Computed tomography of M. Cluster headache is associated with unhealthy PET/MRI for Pediatric Brain and Spinal Cord Tum- PB. Glepaglutide, a novel long-acting glucagon-like sion-weighted MRI in head and neck cancer. Phys 2019;15:9(1):84-92. the chest in unilateral pleural effusions: Outcome lifestyle and lifestyle-related comorbid diseases: ors. J Nucl Med. 2019;60:1053-1058. peptide-2 analogue, for patients with short bowel Med. 2019;61:1-7. Plaschke CC, Gehl J, Johannesen HH, Fischer of the British Thoracic Society guideline. J Thorac Results from the Danish Cluster Headache Survey. Mathiesen IH, Hitz MF, Katzenstein TL, Oturai P, syndrome: a randomised phase 2 trial. Lancet Gas- Palm S, Jensen H, Ekberg C, Albertsson P, Lindegren BM, Kjaer A, Lomholt AF, Wessel I. Calcium Dis. 2019;11(4):1336-1346. Cephalalgia. 2019;39(2):254-263. Skov M, Jørgensen NR, Jensen PO, Mikkelsen troenterol Hepatol. 2019;4(5):354-363. S. Towards elucidating the radiochemistry of asta- electroporation for recurrent head and neck Risom EC, Buggeskov KB, Mogensen UB, Sundskard Lundemann M, Munck Af Rosenschold P, Muhic CR, Krogh-Madsen R, Pressler T, Faurholt-Jeps- Nielsen J, Kjaer MS, Rasmussen A, Borgwardt L, tine - Behavior in chloroform. Scientific Reports. cancer: A clinical phase I study. Laryngoscope M, Mortensen J, Ravn HB. Preoperative pulmo- A, Larsen VA, Poulsen HS, Engelholm SA, An- en D. Markers of bone turnover are reduced in Christensen VB. Findes der prognostiske markører 2019;4;9(1):15900. Investig Otolaryngol. 2019;3;4(1):49-56. nary function in all comers for cardiac surgery pre- dersen FL, Kjaer A, Larsson HBW, Law I, Hansen patients with CF related diabetes; the role of glu- i pædiatrisk leversygdom? Best Practice Nordic Perani D, Iaccarino L, Lammertsma AA, Windhorst Plaschke CC, Johannesen HH, Hansen RH, Hendel dicts mortality. Interact Cardiovasc Thorac Surg. AE. Feasibility of multi-parametric PET and MRI cose. J Cyst Fibros. 2019;18:436-441. Gastroenterologi. 2019:e. AD, Edison P, Boellaard R, Hansson O, Nordberg HW, Kiss K, Gehl J, Wessel I. The DAHANCA 2019;29:244-251.

64 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 65 Publications Podcasts

Schramm G, Ladefoged CN. Metal artifact correction trade ET, Hansen HD, Villadsen J, Erlandsson M, Valladares A, Ahangari S, Beyer T, Boellaard R, with Type 1 diabetes. Eur Heart J Cardiovasc Imag- Liselotte Højgaards strålende kamp mod kræft strategies in MRI-based attenuation correction in Ohlsson T, Yazdani A, Valliant JF, Kristensen JL, Chalampalakis Z, Comtat C, Daltoso L, Hansen ing. 2019;20(7):796-803. Rigshospitalets direktør Per Christiansen tager PET/MRI. BJR Open. 2019;1:20190033 Barz M, Knudsen GM, Kjaer A, Herth MM. Im- AE, Koole M, Mackewn J, Marsden P, Nuyts J, Zurek Munk-Madsen M, Zakarian K, Sandor Oturai en snak med klinikchef og professor Liselotte Simón M, Norregaard K, Jørgensen JT, Oddershede proved radiosynthesis and preliminary in vivo Padormo F, Peeters R, Poth S, Solari E, Rausch I. P, Hansen CP, Federspiel B, Fallentin E, Linno Wil- Højgaard fra Klinik for Fysiologi og Nuklearmedicin LB, Kjaer A. Fractionated photothermal therapy evaluation of the 11C-labeled tetrazine [11C]AE-1 Clinically Valuable Quality Control for PET/MRI lemoe G. Intrapancreatic accessory spleen mim- om nuklearmedicinens kolossale betydning for in a murine tumor model: comparison with single for pretargeted PET imaging. Bioorg Med Chem Systems : Consensus Recommendation From the icking Malignant tumor: three case reports. Acta kræftpatienter, om tåbeligt bureaukrati og kræftsyge dose. Int J Nanomedicine. 2019;14:5369-5379. Lett. 2019;29(8):986-990. HYBRID Consortium. Front Phys. 2019;7:136. Radiol Open. 2019;8:205846011985934 børns som den bedste motivation i kampen mod cancer. Simonsen, H, Cramer SP, Frederiksen JL, Larsson Stéen EJL, Shalgunov V, Denk C, Mikula H, Kjaer Varatharaj A, Lijeroth M, Darekar A, Larsson HBW, Øen SK, Keil TM, Berntsen EM, Aanerud JF, Schwar- HBW. Blod-hjerne-barriere permeabilitet forudser A, Kristensen JL, Herth MM. Convenient Entry to Galea I, Cramer SP. Blood-brain barrier meas- zlmüller T, Ladefoged CN, Karlberg AM, Eikenes to-års behandlingseffekten af Natalizumab eller 18F-Labeled Amines through the Staudinger Reduc- ured using dynamic contrast-enhanced magnetic L. Quantitative and clinical impact of MRI-based Fingolimod ved relapsing-remitting multipel skle- tion. European J Org Chem. 2019(8):1722-1725. resonance imaging: a validation study. J Physiol. attenuation correction methods in [18F]FDG eval- Linda Kragh og indsatsen rose. Best Bractice Neurologi. Februar 2019. Suetta C, Haddock B, Alcazar J, Noerst T, Hansen 2019;597(3):699-709. uation of dementia. EJNMMI Res. 2019;9:83. Ledende bioanalytiker Linda Kragh fra Klinik for Sitter B, Sjøbakk TE, Larsson HBW, Kvistad KA. OM, Ludvig H, Kamper RS, Schnohr P, Prescott Vestergaard MB, Larsson HB. Cerebral metabolism Østergaard ML, Konge L, Kahr N, Albrecht-Beste Fysiologi og Nuklearmedicin har med sine fem årtier Clinical MR spectroscopy of the brain. Tidsskr Nor E, Andersen LL, Frandsen U, Aagaard P, Bülow J, and vascular reactivity during breath-hold and hy- E, Nielsen MB, Nielsen KR. Four Virtual-Reality i sundhedsvæsenet været med til at sætte sit præg Laegeforen. 2019;26:139(6). Hovind P & Simonsen L. The Copenhagen Sarco- poxic challenge in freedivers and healthy controls. Simulators for Diagnostic Abdominal Ultrasound på bioanalytikeruddannelsen. Hendes kolleger på Skougaard K, Østrup O, Guldbrandsen K, Sørensen penia Study: lean mass, strength, power, and phys- J Cereb Blood Flow Metab. 2019;39(5):834-848. Training in Radiology. Diagnostics (Basel). Rigshospitalet må ind i mellem løbe stærkt, der er B, Meldgaard P, Saghir Z, Gørtz P, Lonsdale MN, ical function in a Danish cohort aged 20-93 years. Zarnani K, Nichols TE, Alfaro-Almagro F, Fagerlund 2019;6;9(2). kamp om at skaffe studerende nok til uddannelsen, Frank MS, Gerke O, Rychwicka-Kielek BA, Persson J. Cachexia Sarcopenia Muscle. 2019;10:1316-29. B, Lauritzen M, Rostrup E, Smith SM. Discovering Østergaard ML, Rue Nielsen K, Albrecht-Beste E, men til gengæld er jobbet givende. Hør om at G, Land LH, Schytte T, Bodtger U, Skuladottir H, Tampio L ’Estrade E, Xiong M, Shalgunov V, Edgar markers of healthy aging: a prospective study in Kjaer Ersbøll A, Konge L, Bachmann Nielsen M. tjene menneskeheden, om pladsproblemer og om Søgaard J, Nielsen SS, Rasmussen TR, Fischer BM. FG, Volk B, Baerentzen SL, Palner M, Erlandsson a Danish male birth cohort. Aging (Albany NY). Simultar training improves ultrasound scanning kyllingeben i gelé. Surveillance With PET/CT and Liquid Biopsies of M, Ohlsson, Knudsen GM, Herth MM. Develop- 2019;11(16):5943-5974 performance on patients: a randomized controlled Stage I-III Lung Cancer Patients After Completion of ment and Evaluation of Two Potential 5-HT7 Re- Zhang C, Svensson RB, Couppé C, Schjerling P, trial. Europen Radiology. 2019;29(6):3210-18. Definitive Therapy. A Randomized Controlled Trial ceptor PET Tracers: [18F]ENL09 and [18F]ENL10. Skovgaard D, Kjaer M, Magnusson SP. Regional Østrup O, Nielsen J, Kjaer MS, Borgwardt L, Rasmus- (SUPER). Clin Lung Cancer. 2019;19:1525-7304. ACS Chemical Neuroscience. 2019;10(9):3961- differences in turnover composition and mechan- sen A, Christensen VB. Findes der prognostiske Kunstig intelligens skal hjælpe læger og ikke Skovsgaard MB, Jeppesen TE, Mortensen MR, 3968. ics of the porcine flexor tendon. Connective Tissue markører i pædiatrisk leversygdom? Best Practice erstatte dem Nielsen CH, Madsen J, Kjaer A, Gothelf KV. Af- Timsit JF, Citerio G, Lavilloniere M, Perner A, Smith Research. 2019;28:1-10. Nordic Gastroenterologi. August 2019. Rigshospitalets direktør Per Christiansen besøger finity-Guided Conjugation to Antibodies for Use M, Ruckly S, Basseti M, Bakker J, Benoit D, Cur- Zobel EH, Hasbak P, Winther SA, Hansen CS, Fleis- datalog Claes Nøhr Ladefoged, der arbejder med få in Positron Emission Tomography. Bioconjug tis JR, Curtis JR, Doig G, Herridge M, Jaber S, cher J, von Scholten BJ, Holmvang L, Kjaer A, kunstig intelligens til at hjælpe sundhedspersonale med Chem. 2019;30(3):881-887. Papazian L, Peters M, Singer P, Soares M, Torres Rossing P, Hansen TW. Cardiac Autonomic Func- at få hurtigere og mere præcise diagnoser, samt færre Slipsager JM, Ellegaard AH, Glimberg SL, Pauls- A, Viellard-Baron, Azoulay E. Determinants of tion Is Associated With Myocardial Flow Reserve gener i processen for patienterne. Selv om der er en en RR, Tisdall DM, Wighton P, van der Kouwe downloads and citations for articles published in in Type 1 Diabetes. Diabetes. 2019;68(6):1277- digital revolution på vej, så kan computere ikke erstatte A, Marner L, Henriksen OM, Law I, Olesen OV. Intensive Care Medicine. Intensive Care Medicine. 1286. læger, fortæller Claes Nøhr Ladefoged. Markerless motion tracking and correction for 2019;45(7):1058-1060. Zobel EH, Winther SA, Hasbak P, von Scholten BJ, PET, MRI, and simultaneous PET/MRI. PLOS ONE Tønnesen R, Buch K, Hovind P, Jensen LT, Schwarz P. Holmvang L, Kjaer A, Rossing P, Hansen TW. Myo- 2019;14:1-17 Blood Pressure in Healthy Youngsters is modified cardial flow reserve assessed by cardiac82 Rb posi- Stéen EJL, Jørgensen JT, Petersen IN, Nørregaard by Vitamin-D Supplementation. Endocrinology, tron emission tomography/computed tomography K, Lehel S, Shalgunov V, Birke A, Edem PE, L’Es- Diabetes & Metabolism. 2019;3(2). is associated with albumin excretion in patients

66 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 67 Cluster for Molecular Imaging

Professor Andreas Kjær

1 The paradigm of precision or personalized med- cardiovascular disease. Moreover, successful PET Figure 1. The major steps involved in PET tracer devel- icine, i.e. tailoring therapy to the disease char- imaging ligands may be developed or “converted” opment: after identification of an unmet clinical need, acteristics of the individual patient, has caused a into radionuclide therapies if labeled with alpha selection of the key-process involved in the pathophysiology need for diagnosing at the molecular level. Stand- or beta-emitting isotopes or into optical imaging of the disease and a relevant molecular target is identified. ard molecular biology methods rely on tissue sam- ligands for surgical navigation and guidance. The Thereafter, a specific ligand is developed and labeled with pling for in vitro and ex vivo analyses. However, imaging companion may predict the distribution a suitable radionuclide for imaging (or therapy). Target tissue sampling is prone to sampling error, i.e. the of the therapeutic ligand and thereby if the ther- validation (specificity) is then initially evaluated in vitro non-representativeness of a biopsy with regard apy is likely to work. Such imaging-therapy pairs followed by testing in vivo in relevant animal models where to the disease due to heterogeneity. In contrast, are known as theranostics. also the biodistribution is studied for calculation of radia- molecular imaging allows for non-invasive stud- tion dosimetry. From animals used in vivo, tissue is excised, ies at whole-body level in the intact organism Currently, our molecular imaging and theranos- which then undergo ex vivo investigations, e.g. to confirm and elegantly circumvents this potential error. tics research program focuses on development target binding and expression. Successful, lead candidates Furthermore, because of the unsurpassed sensi- and application of new molecular imaging/ther- are then rigorously tested for possible toxicity according tivity of PET and the possibility to quantify tracer apeutic ligands. Key application areas include, to European guidelines and biological and radiochemical uptake, the use of specific PET tracers for molec- but are not limited to: 1) individual therapy data and procedures form the basis for the Investigational ular imaging of phenotypic characteristics as a planning including companion diagnostics), 2) Medicinal Product Dossier (IMPD), which is part of the ap- basis for practicing personalized medicine holds therapy monitoring and early detection of non-re- plication for human use. Following approval by the health great promise. Among characteristics, which can sponders, 3) drug development, and 4) targeted authorities, a first-in-humans phase I clinical trial may be visualized are the hallmarks of cancer, e.g. radionuclide therapy (theranostics) including then be initiated. If successful, phase II studies of clinical cancer aggressiveness, angiogenesis and cell pro- alpha-emitting ligands. Diseases of particular utility are then pursued. This may be followed by commer- liferation. We foresee that such PET ligands for interest in our translational research program cialization to reach clinical use on a broader basis. Imaging individual phenotyping will become game-chang- include cancer, cardiovascular disease, infection/ ligands may also be used as a starting point for new target- ing within many diseases including cancer and inflammation and metabolic disease. ed therapies, in particular radionuclide based therapies.

68 department of clinical physiology, nuclear medicine & pet 7 3 Figure 2. How we use a Göttingen Minipig model Figure 4. 64Cu-NOTA-CD8a PET imaging of cytotoxic T-cells of athrosclerosis for non-invasive measure-ment of following external radiation therapy (XRT) and CTLA-4 atherosclerosis by PET/MRI is longitudinal monitoring checkpoint inhibition. Note the increased following XRT and of therapies. The model may be used for studies of further increase following checkpoint inhibition. The therapy interventions, e.g. GLP-1 analogues. The imaging findings led to inhibited tumor growth and increased surviv-al (lower of the model have been validated by tissue assessment at the panel). This technology may be used to select patients eligible end of the study. For further details on the model system, for checkpoint inhibi-tion as well as monitoring of the induced which we developed in collaboration with Novo Nordisk immune response during therapy (Kellerman L et al. Mol A/S, please see Ludvigsen TP et al. Atherosclerosis 2019. Imaging Biol 2020).

7 3 Figure 3. uPAR-PET in glioblastoma patient. Clear uptake Figure 5. Study peformed in collaboration with the research of tracer in the tumor and very low background, which is group of Prof. Jens Kastrup on adipose-derived stromal cells encouraging for pursuing uPAR as a therapeutic target, administered in a rat model af acute myocardial infarction. e.g. with our uPAR-targeted radionuclide therapy (images The study used bioluminiscense to track stem cells (top), cine from Kurbegovic S et al.). MRI for measuring left ventricular ejection fraction (LVEF, middle) and 82Rb-PET for measuring perfusion (bottom). The study revealed that stem cells improved perfusion as well as LVEF compared to control group (Follin B et al. Stem Cells Int).

Development of new molecular imaging tracers use over the next years. We continuously focus on mor environment. In this way, we bridge between apies. The goal is to help unfolding the immense tion). For the study of cardiovascular diseases and for PET is a complex process from definition of use and development of more predictive animal xenograft models and first-in-human studies. This potential of immunotherapies that are currently effect of novel therapies, e.g. stem cell therapy target to final use of the tracer in patients. We models for PET tracer and radionuclide therapy bridging is unique. Within cardiovascular disease, hampered by a low response rates. For this pur- (Figure 5), we apply mouse, rat, minipig and rab- have focused on establishing competencies to development. This includes use of orthotopically we use mice, rats, rabbits and (mini)pig models pose, we have developed imaging ligands that can bit models. Many of the models include advanced support this workflow. The major steps involved implanted human xenograft tumors as well as to develop new tracers. The pig model is our “full- track the immune response, e.g. cytotoxic T-cells surgical procedures. We apply various PET tracers in PET tracer development and translation into metastatic cancer models using human cancer cell size” model for myocardial infarction and athero- (CD8). With this platform, we have been able to for the study of cardiovascular disease. patients are shown in figure 1. lines. Increasingly, we use patient-derived tumors sclerosis (Figure 2). predict the response to checkpoint inhibitor block- (PDX) for orthotopic implantation (PDOX) to even ade in various cancers. This technology may serve Some tissue characteristics currently targeted Cluster for Molecular Imaging, headed by Professor better mimic the conditions in cancer patients re- Studies of glioblastoma and use of our new uPAR- for practicing personalized medicine and select for imaging: Andreas Kjær, was established in 2003 at the Fac- garding the tumor microenvironment, which is of PET tracer has continued in animal models with likely responders to immunotherapy in cancer. In 3 Cancer specific receptors ulty of Health and Medical Sciences, University of great importance for tumorigenesis. For the study orthotopically implanted human glioblastoma a recent publication, we were able to demonstrate 3 Glycolytic activity (PET and hyperpolarized Copenhagen as a specialized facility at the Panum of immunotherapies in cancer, we use syngeneic xenograft tumors as well as in glioblastoma pa- how “priming” with external radiotherapy in- MRSI) Institute for molecular imaging in animals with and humanized preclinical models. tients (Figure 3). creased the T-cell (CD8) infiltration of the tumors 3 Cell proliferation PET, SPECT, CT, MRI and optical imaging. This is and subsequent use of the checkpoint inhibitor 3 Amino acid transport a key component of our translational capabilities For more than a decade, we have worked on re- With the increasing use of immunotherapies, in thereafter further increased and sustained a T-cell 3 Angiogenesis since it allows us to test new tracers and radionu- fining our translational platform for development particular checkpoint inhibitors, that support the response leading to increase in survival (Figure 4). 3 Hypoxia clide therapies in animal models as basis for selec- of new PET tracers. With respect to cancer, the immune system to fight cancers we have establish 3 Apoptosis tion and translation into clinical use. Accordingly, platform includes early use of promising PET numerous models of syngeneic cancers as well as Within cardiovascular research, we have intro- 3 Necrosis we currently have a broad pipeline of PET tracers tracers in companion dogs with spontaneous humanized (with regard to the immune system) duced and further developed animal models of 3 Invasive cancer phenotype and radionuclide therapies in pre-clinical testing. tumors scheduled for cancer therapy. This allows animal models. Only by using such models, is it cardiovascular diseases including models of ather- 3 Atherosclerotic plaque vulnerability We expect several of these candidates to be taken for testing in “full-size” as well as evaluation of possible to study the interaction between cancer osclerosis, myocardial infarction and heart failure 3 Immune-response into clinical trials and become available for human tumor-stroma interaction due to the syngeneic tu- and the immune system as well as immunother- (both with reduced and preserved ejection frac- 3 Myocardial perfusion

70 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 71 Research

Professor Andreas Kjær

A continuous focus on research and development tion and phenotyping are ongoing. These novel PET/MRI is a key activity and focus area of our Depart- tracers will be used for diagnosing, staging, risk Being one of the first departments to install a ment. We have over the years build a comprehen- stratification, and therapy planning and monitor- combined PET/MRI scanner, we established a sive research program directed at developing in- ing. Tracers developed at our department, and comprehensive research program on PET/MRI novative solutions to solve unmet clinical needs. taken first-in-humans by us, include64 Cu-DO- with focus on the added value of combining mo- We constantly adjust our research program to TATATE, 64Cu-DOTA-AE105, 68Ga-NOTA-AE105, lecular imaging with PET and multiparametric 68 18 be clinically relevant and timely. Our research Ga-NODAGA-RGD2 and F-ASIS. Once taken MRI. A large number of clinical trials have been program is built on our strong in-house com- successfully first-in-humans, we study in phase finalized or are ongoing with this purpose. The petencies as well as on strategic collaborations II clinical trials the utility of the tracers in the ambition is to improve tissue characterization with leading international and national research clinical setting to establish where they may be and response monitoring ability in cancer treat- groups with complementary competencies and of particular value to the patients. Accordingly, ment, pediatric studies, brain studies and ather- capabilities. The focus of our research program 68Ga-NOTA-AE105, which is a marker of cancer osclerotic plaque characterization. Focus of MRI is development of new tracers for PET, PET/MRI aggressiveness and metastatic potential (the inva- includes the use of diffusion weighted images hybrid imaging, radionuclide therapies (theranos- sive phenotype) has been tested in two completed (DWI) / apparent diffusion coefficient (ADC) and tics), clinical evaluation of new diagnostic meth- and 7 ongoing phase II trials in various cancer magnetic resonance spectroscopy (MRS). With 68 ods, the use of methods from clinical physiology types (Figure 1). Likewise, Ga-NODAGA-RGD2, access to matching preclinical PET and 7T MRI, and nuclear medicine to study pathophysiology an angiogenesis PET tracer, is currently tested in we can work translational in developing and and application of machine learning and artificial Phase II clinical trials. evaluating new methods. As an example, the use intelligence in imaging. Translational research in of PET/MRI for radiation therapy planning and molecular imaging is given special attention in Over the years, we have build a comprehensive response monitoring is being evaluated both pre- order to accelerate translation of new tracers into platform for validation of new tracers, including clinically and clinically. Also, the added value of clinical use in patients. Current major research cell laboratory, molecular biology (proteomics multiparametric imaging combining information areas are briefly described below. and genomics), histology and biomarker labora- from both PET and MRI is currently studied. tory. We currently have additional promising new New tracers PET tracers in our developmental pipeline and ex- hyperPET Numerous projects aimed at development of new pect a continuous translation of the best of these Our department was the first to install a dynamic PET tracers for non-invasive tissue characteriza- into clinical use over the next years. nuclear polarized (DNP) for hyperpolarization of

72 department of clinical physiology, nuclear medicine & pet 7 Research Figure 1 showing uPAR-PET/CT (B, C) and CT (A, C) imaging in 2 patients with neuroendocrine carcinomas from an ongoing phase II clinical trial. Upper row (A, B): Bronchopulmonary NEC. Lower row (D, D): Large subcutaneous metastasis from primary colon G3/NEC (Images from Carlsen EA et al.) forma- tion may allow for better cancer phenotyping and be used for personalizing therapy (Images from Clemmensen A et al.)

3 Figure 2 showing first non-FDG hyperPET combining angio- genesis 68Ga-RGD-PET (B) with hyperpolarized 13C-pyruvate magnetic resonance spectroscopty (MRS) imaging of me- tabolism (B) in two canine sarcoma cancer patients. Tumor delineation drawn on basis of anatomical MRI (A) are shown in green. Combined angiogenesis and metabolic information may allow for better cancer phenotyping and be used for per- sonalizing therapy (Images from Clemmensen A et al.)

13C-labeled compounds next to a PET/MRI scan- Clinical PET/CT in oncology ing of PET and SPECT, are carried out in coopera- used for research in neurobiology. The focus has ner. We have used this set-up for development of A large number of prospective clinical protocols tion with clinical departments, particularly within mainly been on the serotonergic system. and research in the combination of hyperpolar- aimed at evaluation of the diagnostic and prog- oncology and function of the hepato-biliary sys- ized 13C-MRS and PET, a combination we named nostic value of PET/CT using various tracers, tem. Also targeted radionuclide therapy for cancer Functional MR hyperPET. SO far, we have focused on the use of including the ones developed in-house, are cur- in children is currently an area of intense interest. Many brain studies using functional MR are hyperPET for tissue characterization in cancer, rently undertaken. The studies are performed in Finally, the use of PET/MRI in children to save ra- undertaken in close collaboration with clinical cardiovascular disease and inflammation/infec- various types of cancer and both in children and diation dose is studies. departments including neurology and psychiatry. tion. Using 13C-pyruvate, we have continued our in adults. Head-to-head comparison of new PET A particular area of interest is development of studies of the Warburg effect and its relation to tracers and established imaging methods is also Neuro PET new methods and clinical application of new func- glucose uptakes as measured by FDG. We have an area of interest. The use of PET/CT for the Brain tumor studies are currently undertaken using tional and molecular MR methods. Methods are found, that FDG only in part reflects the Warburg planning of radiation therapy (“dose-painting”) PET/MR, PET/CT and HRRT PET. Brain tumors aimed at obtaining information on tissue physiol- effect. Recently, we also combined13 C-pyruvate and the use of respiratory gating are also current- are in particular studied with the amino acid tracer ogy, organ perfusion, and molecular biology. with a non-FDG PET tracer, e.g. the angiogenesis ly being evaluated. Many of these studies also FET but also with several of our novel in-house 68 tracer Ga-NODAGA-RGD2. In addition, we also include PET/MRI to study the added value com- developed tracers, e.g. uPAR-targeting ligands. Atherosclerosis studied non-pyruvate 13C-compounds, e.g. 13C-fu- pared to PET/CT. Studies of brain perfusion using PET or DCE-CT are Visualization of atherosclerosis non-invasively marate, and indicator of necrosis, in hyperPET also performed. In addition, attention is given to and prediction of plaque vulnerability in athero- studies. Based on our results obtained so far, Pediatric nuclear medicine investigations imaging of dementia using various new tracers. In sclerosis using PET/MRI and PET/CT is intensive- hyperPET may be superior in cancer phenotyping The department undertakes many pediatric in- cooperation with Neurobiology Research Unit and ly studies both preclinically and in clinical studies. and response monitoring and has the potential for vestigations including participation in an array of Centre for Integrated Molecular Brain Imaging, In particular, the quantification of low-grade future clinical use. prospective studies. These research protocols, us- neuroreceptor ligands have been developed and vascular inflammation has become a focus area

74 department of clinical physiology, nuclear medicine & pet Research

and is now used in several clinical trials on cardio- transplantation and endobronchial stenting for is given to development of new PET ligands for near-infrared (NIR) optical probes to be used for vascular risk and mode-of-action studies in GLP-1 emphysema, are performed. Accordingly, we specific imaging of the immune response, e.g. intraoperative delineation of cancer. The methods therapies. In addition, patient groups at risk are have previously demonstrated the increased macrophage, CD4 and CD8 imaging. These tracers ensures to a larger extent negative margins and studied and special focus is on the value of new value of combined use of SPECT/CT for diagnos- will also be applicable within immune oncology, spares functional tissue that may be critical, e.g. specific PET tracers, e.g. for the study of mac- ing pulmonary embolism compared to CT only. where they can serve to better understand the in the brain. The optical guidance is expected to rophage activation by 64Cu-DOTATATE. Clinically, Continious research is also being conducted into mechanisms behind immune response during tu- lead to better patient outcome, including overall our ambition is to provide image-based risk strat- mucociliary clearance, a method pioneered at morigenesis and as a tool to select patients eligible survival and quality of life. The methods will work ification to select patients that will benefit from the department, of the nose and lungs. Finally, for specific immunotherapies. in synergy with PET, as a preoperative PET scan of vascular surgery. Also, we were the first to publish the department is participating in a large study the same target will predict whether use of optical data showing advantage of PET/MRI over PET/ colleting data for a lung function test reference Radionuclide therapy and theranostics imaging is feasible. We expect the technology to CT for carotid artery imaging and we continue to database. An ever increasing attention is directed towards become an enabler of performing semi-automated refine and develop vascular imaging using PET/ development and use of targeted radionuclide robotic surgery where robots can be guided by MRI with novel PET tracers. Studies of muscle function therapy using both beta- or alpha-emitting specific these imaging signals. With the use of methods from clinical physiology ligands targeting relevant cancer characteristics. Nuclear cardiology and nuclear medicine as well as molecular anal- The department takes part in research within Whole body counting Taking advantage of the ability to quantify my- yses, muscle function, bone density, and body this area by testing new ligands and producing Together with external collaborators, we apply ocardial perfusion in absolute terms and myo- composition are studied. The current focus is on relevant therapeutic isotopes. Most notably, we whole body counting for precise measurements cardial flow reserve by82 Rb PET, we study these the effect of exercise, immobilization, and aging. also in-house develop new theranostics based of body composition. Moreover, studies on the parameters in various cardiovascular diseases. In addition, data are collected on the same param- on promising imaging ligands, which are then absorption of certain minerals from the gastroin- This includes studies on how interventions as eters from a population-based study. These data labeled with beta or alpha emitting radionuclides. testinal tract are undertaken. stem cell therapy, gene therapy and pharmacolog- will serve as a reference database and elucidate Cancers that are currently being targeted clinical- ical treatment affects myocardial perfusion and markers to predict aging-related diseases. ly include glioblastomas,neuroendocrine tumors, Clinically applied artificial intelligence integrated vasomotor function. With the use PET/ prostate and colorectal cancer. Development of In a number of projects we currently study how to CT, the development of ischaemic heart diseases Immune cell tracking therapeutic radioligands is largely based on im- exploit artificial intelligence/machine learning in is studied in selected groups of patients, e.g. pa- At present, we strongly focus s on development of aging with the same ligand as the therapy (ther- medical imaging. These studies cover most of the tients with diabetes, HIV, CMV infection and hep- non-invasive imaging tools for visualizing the im- anostics). The concept of a tracer that visualizes imaging modalities and disease areas we currently atitis. On basis of this, better screening algorithms mune response and tracking immune cells. These the target prior to starting therapy is also known work with, e.g. oncology, brain and cardiovascu- for early detection of ischaemic heart disease are methods will be used in studies of inflammation, as companion diagnostics. lar. Examples of studies performed include how to developed. infection, rejection and immune oncology. In generate synthetic CT attenuation maps from MR some studies, the added value of MR-derived pa- Image guided surgery scans, how radiotracer doses may be reduced and Lung studies rameters of PET/MR is also studied. Our depart- Optical guided cancer surgery is a relatively new how to perform automated image interpretation A large number fo studies using lung function ment is a partner in the PERSIMUNE program, concept. In collaboration withseveral surgical from segmentation to clinical outcome. Increas- testing and lung scintigraphy in different pa- personalized medicine of infection complications departments, we develop our most promising ingly, also non-imaing data will be integrated in tient groups ar ongoing, e.g. studies in lung in immune deficiency. Currently, special attention PET ligands targeting cancer specific targets into the studies.

76 department of clinical physiology, nuclear medicine & pet Collaboration with The National Hospital of the Faroe Islands

Professor Jann Mortensen and Chief Physicist Thomas Levin Klausen

Landssjúkrahúsið was founded in 1924 in Tórshavn. Second opinion on scintigraphies and lung function It was originally named Dronning Alexandrines measurements is provided via a direct telemedicine Hospital after the Danish Queen. In the 1960’s the connection. The responsible physician and physicist hospital was expanded and officially declared the for nuclear medicine in Tórshavn is Consultant, National Hospital of the Faroe Islands. Recently it Professor, DMSc Jann Mortensen and Chief Physicist merged with the two smaller hospitals in Klaksvík Thomas Levin Klausen. and Tvøroyri into one hospital system with joint leadership. The National Hospital of the Faroe Is- In 2019, the Department of Clinical Physiology and lands serves The Faroe Islands population of 51,000. Nuclear Medicine in Tórshavn performed around 500 scintigraphies of lungs, bones, thyroid, kidneys The National hospital has 850 employees and 120 and renographies on the department´s 2-headed beds. The 9,000 in-patients and 60,000 out-patients Skylight camera. Nearly 500 lung functions tests annually are taken care of by 29 medical specialties, were performed with the Jaeger whole body ple- of which 9 are via consultant collaborations, includ- thysmograph and close to 600 routine and research ing collaboration in clinical physiology and nuclear DXA studies were performed with The Norland DXA medicine with our department at Rigshospitalet. 840 scanner.

78 department of clinical physiology, nuclear medicine & pet Neurobiology Research Unit

We appreciate the excellent collaboration with Professor Gitte Moos Knudsen, Head of the Neurobiology Research Unit (NRU) at Rigshospitalet, University of Copenhagen and also Director of the Lundbeck Foundation's Center for Integrated Molecular Brain Imaging (CIMBI) and Innovation Fund Denmark Center for Experimental Medicine NeuroPharmacology (NeuroPharm). The research focus of NRU is neurobiology, physiology and pathophysiology, molecular imaging and neuroreceptor ligands with focus on the serotonergic system. nru.dk | cimbi.dk | neuropharm.eu

80 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 81 Bioengineer in Medicine and Technology

In cooperation with the Technical University of Denmark (DTU) and the University of Copenhagen (KU), the department represented by Professor Liselotte Højgaard is involved in the Bioengineer program in Medicine and Technology at bachelor and master level. You can read more about the program at dtu.dk/bme.

At present several of these bioengineers are seconded to the department as PhD students, and we have numerous students working with bachelor and master reports in collaboration with DTU.

82 department of clinical physiology, nuclear medicine & pet department of clinical physiology, nuclear medicine & pet 83 Editors Liselotte Højgaard Vibeke Rønn

Layout Eckardt ApS

Print Specialtrykkeriet Viborg

Photos Signe Fiig Sophie Kalckar Joachim Rohde

Drawings Lars Andersen

Issues 1000 ex.

Copyright Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet University of Copenhagen Blegdamsvej 9 DK 2100 Copenhagen Ø Denmark

Contact Professor Liselotte Højgaard E-mail: [email protected] Phone: +45 3545 4215 Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet, KF Section 4011 Blegdamsvej 9 2100 Copenhagen Ø, Denmark Telephone: +45 3545 4011 Fax no: +45 3545 4015 Mail: [email protected]

Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet, PET Section 3982 Blegdamsvej 9 2100 Copenhagen Ø, Denmark Telephone: +45 3545 3919 Fax no: +45 3545 3898 Mail: [email protected]

Department of Clinical Physiology, Nuclear Medicine & PET Rigshospitalet, Glostrup Section Valdemar Hansens Vej 13 Entrance 1, 2nd floor 2600 Glostrup Telephone: +45 3863 2434 Fax no: +45 3863 3928 Mail: [email protected] www.rigshospitalet.dk/afdelinger-og-klinikker/ diagnostisk/klinik-for-klinisk-fysiologi-nuklearmedicin-og-pet

Going green